[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2584
1. Pineda RH, Heiser RA, Ribera AB: Developmental, molecular, and genetic dissection of INa in vivo in embryonic zebrafish sensory neurons. J Neurophysiol; 2005 Jun;93(6):3582-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MOs were injected into one-cell stage embryos, and RB sodium currents were recorded using patch-clamp techniques in both conventional whole cell mode as well from nucleated patches.
  • These results indicate that MOs are a useful tool for the molecular dissection and analysis of ion channel function in vivo.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15673553.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS-38937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Sodium Channel Blockers; 0 / Sodium Channels; 4368-28-9 / Tetrodotoxin
  •  go-up   go-down


2. Arik Z, Ozkan C, Ozdemir E, Altundag K: Breast cancer in a patient with agnogenic myeloid metaplasia. South Med J; 2010 Oct;103(10):1075-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in a patient with agnogenic myeloid metaplasia.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Primary Myelofibrosis / complications

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818318.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


3. Bock O, Loch G, Schade U, Büsche G, Wasielewski R, Wiese B, Kreipe H: Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. Br J Haematol; 2005 Jul;130(1):76-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
  • Advanced chronic idiopathic myelofibrosis (IMF) with osteosclerosis and increase and thickening of bone trabeculae is typically contrasted by the absence or sparse presence of osteoclasts.
  • Because osteoclast formation can be inhibited by osteoprotegerin (OPG) we investigated OPG expression in IMF with severe fibrosis and osteosclerosis, which expressed significantly higher (up to 71-fold) OPG mRNA levels when compared with prefibrotic cellular IMF and control cases.
  • Case-specific calculation of the RANKL/OPG ratio in advanced IMF showed a wide range without significant differences when compared with the prefibrotic IMF and non-neoplastic haematopoiesis.
  • [MeSH-major] Endothelial Cells / metabolism. Glycoproteins / metabolism. Osteosclerosis / etiology. Primary Myelofibrosis / complications. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Tumor Necrosis Factor / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Carrier Proteins / genetics. Female. Fibroblasts / chemistry. Humans. Immunohistochemistry / methods. Male. Megakaryocytes / chemistry. Membrane Glycoproteins / genetics. Middle Aged. Osteoclasts / pathology. Osteoprotegerin. RANK Ligand. RNA, Messenger / analysis. Receptor Activator of Nuclear Factor-kappa B. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982347.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Membrane Glycoproteins; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11A protein, human; 0 / TNFRSF11B protein, human; 0 / TNFSF11 protein, human
  •  go-up   go-down


Advertisement
4. Oh TH, Stueve MH, Hoskin TL, Luedtke CA, Vincent A, Moder KG, Thompson JM: Brief interdisciplinary treatment program for fibromyalgia: six to twelve months outcome. Am J Phys Med Rehabil; 2010 Feb;89(2):115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the impact and long-term benefit of a brief 1(1/2)-day fibromyalgia treatment program.
  • We administered three self-reported instruments: the Fibromyalgia Impact Questionnaire, the Short Form-36 Health Status Questionnaire, and a satisfaction survey, at baseline, and 6-12 mos after completing the fibromyalgia treatment program.
  • CONCLUSIONS: A brief 1(1/2)-day fibromyalgia treatment program improves symptoms and quality of life in patients with fibromyalgia for 6-12 mos.

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090427.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Tangen E, Conradie J, Ghosh A: The challenge of being straight: explaining the linearity of a low-spin [FeNO]7 unit in a tropocoronand complex. Inorg Chem; 2005 Nov 28;44(24):8699-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of being straight: explaining the linearity of a low-spin [FeNO]7 unit in a tropocoronand complex.
  • The calculations accurately reproduce the experimentally observed trigonal-bipyramidal geometry of this complex, featuring a linear NO in an equatorial position and a very short Fe-N(NO) distance.
  • Thus, there is a close correspondence between the molecular orbitals (MOs) in the two cases.
  • However, there is a critical, if somewhat subtle, difference in the nature of the singly occupied MOs (SOMOs) between the two.
  • Apparently, such a d orbital is less adept at sigma bonding with NO and, as such, pi bonding dominates the Fe-NO interaction, leading to an essentially linear FeNO unit and a short Fe-N(NO) distance.
  • [MeSH-major] Ferric Compounds / chemistry. Models, Molecular. Nitric Oxide / chemistry. Porphyrins / chemistry

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16296823.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Ligands; 0 / Porphyrins; 31C4KY9ESH / Nitric Oxide; 42VZT0U6YR / Heme
  •  go-up   go-down


6. Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R: Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood; 2010 Dec 23;116(26):5972-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
  • Because primary myelofibrosis (PMF) originates at the level of the pluripotent hematopoietic stem cell (HSC), we examined the effects of various therapeutic agents on the in vitro and in vivo behavior of PMF CD34(+) cells.
  • Two to 6 months after the transplantation of CMAs treated JAK2V617F(+) PMF CD34(+) cells into nonobese diabetic/severe combined immunodeficient (SCID)/IL-2Rγ(null) mice, the percentage of JAK2V617F/JAK2(total) in human CD45(+) marrow cells was dramatically reduced.
  • Sequential treatment with CMAs, therefore, represents a possible effective means of treating PMF at the level of the malignant SRC.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2005 May;29(5):511-5 [15755503.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):587-95 [17379069.001]
  • [Cites] Exp Hematol. 2006 Feb;34(2):140-9 [16459182.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3128-34 [16757685.001]
  • [Cites] PLoS Med. 2006 Jul;3(7):e270 [16834459.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3428-32 [17178722.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3570-8 [17185465.001]
  • [Cites] Drugs Today (Barc). 2007 Jun;43(6):395-422 [17612710.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6417-24 [17616702.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1472-81 [17701577.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1247-52 [17962618.001]
  • [Cites] Leukemia. 2008 Jan;22(1):23-30 [17882282.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):1920-30 [18511598.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] Nat Immunol. 2001 Jan;2(1):75-82 [11135582.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2023-31 [11877275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):558-66 [12406101.001]
  • [Cites] Int J Hematol. 2002 Aug;76 Suppl 2:193-203 [12430925.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4272-90 [12393615.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4102-10 [14976039.001]
  • [Cites] Oncogene. 2004 Oct 14;23(47):7846-53 [15361842.001]
  • [Cites] Curr Opin Hematol. 1999 Mar;6(2):100-9 [10088640.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):1-13 [15572213.001]
  • [Cites] Science. 2009 May 15;324(5929):930-5 [19372391.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7612-8 [19752087.001]
  • [Cites] Leukemia. 2010 Jun;24(6):1128-38 [20428194.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • (PMID = 20858855.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108671; United States / NCI NIH HHS / CA / 1P01CA108671
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Chromatin; 0 / Hydroxamic Acids; 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 3X2S926L3Z / trichostatin A; 58IFB293JI / vorinostat; 776B62CQ27 / decitabine; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3031385
  •  go-up   go-down


7. Mavalankar D, Callahan K, Sriram V, Singh P, Desai A: Where there is no anesthetist--increasing capacity for emergency obstetric care in rural India: an evaluation of a pilot program to train general doctors. Int J Gynaecol Obstet; 2009 Dec;107(3):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where there is no anesthetist--increasing capacity for emergency obstetric care in rural India: an evaluation of a pilot program to train general doctors.
  • In 2006, the state of Gujarat initiated the Life Saving Anesthetic Skills (LSAS) for Emergency Obstetric Care (EmOC) training program for medical offers (MOs).
  • We evaluated the trained MOs' experience of the program, and identified factors leading to post-training performance.
  • METHODS: The sample was chosen to equally represent performing and nonperforming LSAS-trained MOs using purposive sampling qualitative interviews with trainees across Gujarat (n=14).
  • RESULTS: Being posted with a specialist anesthesiologist and with a cooperative EmOC provider increased the likelihood that the MOs would provide anesthesia.
  • MOs who did not provide anesthesia were more likely to have been posted with a nonperforming or uncooperative EmOC provider and were more likely to have low confidence in their ability to provide anesthesia.
  • A separate team of program managers who plan, monitor, and solve the problems reported by the trained MOs would further enhance the success of scaling up the training program.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846088.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Azhir A, Riopel J, Solez K, Grynoch R, Sis B: Osseous and myeloid metaplasia in a failed renal allograft. Kidney Int; 2007 Apr;71(8):829-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous and myeloid metaplasia in a failed renal allograft.
  • [MeSH-major] Bone and Bones / pathology. Graft Rejection / complications. Kidney / pathology. Kidney Transplantation / adverse effects. Primary Myelofibrosis / etiology
  • [MeSH-minor] Adult. Female. Humans. Metaplasia / etiology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Kidney Int. 2006 Aug;70(3):407 [16871250.001]
  • (PMID = 17429425.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


9. Banovic I, Gilibert D, Cosnes J: Crohn's disease and fatigue: constancy and co-variations of activity of the disease, depression, anxiety and subjective quality of life. Psychol Health Med; 2010 Aug;15(4):394-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crohn's disease and fatigue: constancy and co-variations of activity of the disease, depression, anxiety and subjective quality of life.
  • Fatigue in Crohn's disease (CD) is considered as a consequence of the disease and its treatment.
  • If research showed the impact of the activity of the disease on vitality, patients can express fatigue even if the disease is inactive.
  • Sleep disturbances are now considered in inflammatory bowel disease (IBD) and they could be involved in fatigue.
  • Fatigue (MFI), depression (HAD-D), anxiety (HAD-A), sleep disturbances (ISI, IQPS), subjective quality of life (Mos-SF36) and activity of the disease (CDAI) were assessed twice with a one-year interval.
  • Moreover, if depression, anxiety, quality of life, and fatigue followed the same course of activity of the disease only during one visit, CDAI did not correlate with these dimensions between visits.
  • [MeSH-major] Anxiety. Crohn Disease / complications. Depression. Fatigue / etiology. Quality of Life


10. Tonnies H, Gerlach A, Heineking B, Starke H, Neitzel H, Neumann LM: Molecular cytogenetic identification and characterization of a de novo supernumerary neocentromeric derivative chromosome 13. Cytogenet Genome Res; 2006;114(3-4):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic identification and characterization of a de novo supernumerary neocentromeric derivative chromosome 13.
  • We report a young girl with microphthalmia, conductive deafness, aortic isthmus stenosis, laryngomalacia, and laryngeal stenosis carrying a de novo supernumerary neocentromeric derivative chromosome 13.
  • The presence of a functional and active neocentromere on the derivative chromosome 13 was confirmed by positive immunofluorescence signals with CENP-C antibodies.
  • Thus the patient had a mosaic conventional karyotype mos 47,XX,+inv dup(13)(qter-->q21.3::q21.3-->q31.3-->neo-->q31.3-->qter)[6]/46,XX [49].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16954674.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Nagata K, Shimoda K: [Myeloproliferative diseases caused by JAK2 mutation]. Rinsho Byori; 2009 Apr;57(4):357-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myeloproliferative diseases caused by JAK2 mutation].
  • Polycythemia vera (PV), essential thrombocythemia(ET), and primary myelofibrosis (PMF) share common clinical features, being clonal disorders of multipotent progenitors.
  • A higher expression of JAK2 V617F would favor erythrocytosis, and a lower one would favor thrombocytosis.
  • This may suggest that the expression levels of JAK2 V617F directly determine which cell lineages increase, possibly leading to the diversity of myeloproliferative diseases.
  • Although only V617F JAK2 may cause myeloproliferative disease (MPD), clonogenic assay, analysis of familial MPD patients, and examination of JAK2 mutation in acute leukemia patients transformed from MPD show that there are additional somatic mutations which contribute to the pathogenesis of V617F JAK2 positive PV, ET, and PMF.
  • [MeSH-major] Janus Kinase 2 / genetics. Janus Kinase 2 / physiology. Mutation. Myeloproliferative Disorders / genetics
  • [MeSH-minor] Humans. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489438.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 22
  •  go-up   go-down


12. Saroch M, Srivastava S, Fink D, Chandra A: Room Temperature Ammonia Gas Sensing Using Mixed Conductor based TEMPOS Structures. Sensors (Basel); 2008 Oct 14;8(10):6355-6370
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current/voltage characteristics of mixed (ion+electron) conductor-based 'TEMPOS' (Tunable Electronic Material with Pores in Oxide on Silicon) structures are reported.
  • TEMPOS are novel electronic MOS-like structures having etched swift heavy ion tracks (i.e., nanopores) in the dielectric layer filled with some conducting material.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiology. 1999 Oct;145 ( Pt 10):2691-9 [10537191.001]
  • [Cites] J Nanosci Nanotechnol. 2003 Aug;3(4):277-93 [14598441.001]
  • [Cites] Science. 1994 Dec 23;266(5193):1961-6 [17836514.001]
  • [Cites] Talanta. 1996 Jan;43(1):125-34 [18966472.001]
  • (PMID = 27873874.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Etched ion tracks / TEMPOS structures / ammonia sensors / impedance measurements
  •  go-up   go-down


13. Marie-Ludivine CD, Papouin G, Saint-Val P, Lopez A: Effect of adapted karate training on quality of life and body balance in 50-year-old men. Open Access J Sports Med; 2010;1:143-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Aging is associated with a decrease in physical skills, sometimes accompanied by a change in quality of life (QOL).
  • Testing sessions, involving completion of the MOS 36-item Short Form Health Survey (SF36) and Beck Depression Inventory, as well as motor and effort evaluation, were done at baseline, and six and 12 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24198552.001).
  • [ISSN] 1179-1543
  • [Journal-full-title] Open access journal of sports medicine
  • [ISO-abbreviation] Open Access J Sports Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3781864
  • [Keywords] NOTNLM ; aging / balance / karate / sport / training
  •  go-up   go-down


14. Lee HC, Tseng WA, Lo FY, Liu TM, Tsai HJ: FoxD5 mediates anterior-posterior polarity through upstream modulator Fgf signaling during zebrafish somitogenesis. Dev Biol; 2009 Dec 15;336(2):232-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This finding was consistent with results obtained from Tg(hsp70l:dnfgfr1-EGFP)pd1 embryos, whose dominant-negative form of FGFR1 was produced by heat-induction.
  • Loss of FoxD5 expression was observed in the embryos injected with fgf3-/fgf8-double-morpholinos (MOs).


15. Boccia A, Marrani AG, Stranges S, Zanoni R, Alagia M, Cossi M, Iozzi MF: Symmetry breaking effect in the ferrocene electronic structure by hydrocarbon-monosubstitution: an experimental and theoretical study. J Chem Phys; 2008 Apr 21;128(15):154315
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present here the results of a synchrotron radiation-excited UV-photoemission investigation and density functional theory calculations on a structurally related series of organometallic free molecules: ethylferrocene (EtFC), vinylferrocene (VFC), and ethynylferrocene (EFC).
  • The broken symmetry of ferrocene caused by the monosubstitution has notable effects on the removal of the molecular orbital (MO) degeneracy which is found to be especially remarkable for the ferrocenelike e(1)' MOs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FERROCENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433217.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferrous Compounds; 0 / Hydrocarbons; U96PKG90JQ / ferrocene
  •  go-up   go-down


16. Harris-Haywood S, Sylvia-Bobiak SN, Stange KC, Flocke SA: The association of how time is spent during outpatient visits and patient satisfaction: are there racial differences? J Natl Med Assoc; 2007 Sep;99(9):1061-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This cross-sectional study employed direct observation of outpatient visits and surveys of 2,502 adult African-American and Caucasian outpatients visiting 138 primary care physicians in 84 family practices in Northeast Ohio.
  • Patient satisfaction was measured using the Medical Outcome Study (MOS) nine-item Visit Rating Scale.
  • Time use was assessed with the Davis Observation Code, which was used to classify every 20 seconds of a visit into 20 behavioral categories.
  • No difference was found between African-American and Caucasian patients in the association between patient satisfaction with a physician and the time the physician spent chatting, planning treatment, providing health education, structuring the interaction, assessing health knowledge or answering patient questions.


17. Krijnen P, van Jaarsveld BC, Hunink MG, Habbema JD: The effect of treatment on health-related quality of life in patients with hypertension and renal artery stenosis. J Hum Hypertens; 2005 Jun;19(6):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quality of life was measured using a questionnaire on physical symptoms associated with hypertension and antihypertensive drugs, and two generic health questionnaires (MOS Survey and EuroQol instrument).
  • They reported similar physical complaints, however, and a similar quality of life.

  • Genetic Alliance. consumer health - Renal artery stenosis.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759023.001).
  • [ISSN] 0950-9240
  • [Journal-full-title] Journal of human hypertension
  • [ISO-abbreviation] J Hum Hypertens
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  •  go-up   go-down


18. Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A: [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Orv Hetil; 2006 Nov 12;147(45):2175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
  • Chronic myeloproliferative disorders are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages in the bone marrow.
  • The WHO classification describes six major groups of chronic myeloproliferative disorders, as follows: chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
  • The diagnosis of chronic myeloid leukemia and certain types of chronic eosinophilic leukemia are based on the detection of fusion genes (in chronic myeloid leukemia the BCR/ABL fusion gene, and in chronic eosinophilic leukemia the FIP1L1-PDGFRalpha gene).
  • On the other hand molecular markers for polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis were lacking, making it difficult to identify these disorders clearly.
  • The authors investigated the incidence of the newly identified somatic point mutation V617F of the Janus-2 tyrosine kinase in patients with polycythemia vera, essential thrombocythemia and myelofibrosis.
  • Janus-2 kinase is a cytoplasmic, non-receptor protein-tyrosine kinase with a key role in signal transduction from multiple hematopoietic growth factor receptors.
  • The mutant protein is constitutively phosphorylated and is able to activate its downstream signaling pathways in the absence of any cytokine, thereby contributing to the pathogenesis of chronic myeloproliferative disorders.
  • The authors investigated DNA samples from 132 patients with chronic myeloproliferative disorders.
  • Approximately 73% of polycythemia vera, 60% of essential thrombocythemia and 67% of myelofibrosis showed the JAK2 V617F mutation.
  • Using the amplification refractory mutation system assay, the frequency of homozygotes was 17.5% in polycythemia vera, 5.4% in essential thrombocythemia and 0% in myelofibrosis.
  • [MeSH-major] Janus Kinase 2 / genetics. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Point Mutation
  • [MeSH-minor] Alleles. Amino Acid Sequence. Base Sequence. Biomarkers, Tumor / analysis. Genetic Markers. Humans. Leukemia / diagnosis. Leukemia / genetics. Molecular Sequence Data. Phenylalanine. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Polymerase Chain Reaction / methods. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics. Signal Transduction. Thrombocytopenia / diagnosis. Thrombocytopenia / genetics. Valine

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17402211.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 47E5O17Y3R / Phenylalanine; EC 2.7.10.2 / Janus Kinase 2; HG18B9YRS7 / Valine
  •  go-up   go-down


19. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC: p53 activation by knockdown technologies. PLoS Genet; 2007 May 25;3(5):e78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morpholino phosphorodiamidate antisense oligonucleotides (MOs) and short interfering RNAs (siRNAs) are commonly used platforms to study gene function by sequence-specific knockdown.
  • Using the zebrafish embryo as a template, correct and mistargeting effects are readily discernible through direct comparison of MO-injected animals with well-studied mutants.
  • We show here indistinguishable off-targeting effects for both maternal and zygotic mRNAs and for both translational and splice-site targeting MOs.
  • We show here that MO off-targeting results in induction of a p53-dependent cell death pathway. p53 activation has also recently been shown to be an unspecified off-target effect of siRNAs.


20. Suzuki H, Tsukahara T, Inoue K: Localization of c-mos mRNA around the animal pole in the zebrafish oocyte with Zor-1/Zorba. Biosci Trends; 2009 Jun;3(3):96-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of c-mos mRNA around the animal pole in the zebrafish oocyte with Zor-1/Zorba.
  • Mos protein, which is coded on the c-mos gene, promotes oocyte maturation and is involved in MAP-kinase signaling pathway.
  • In Xenopus, maternally supplied c-mos mRNA undergoes poly(A) addition, and translational activation via CPE (cytoplasmic polyadenylation element) and CPEB (CPE binding protein).
  • The elongated poly(A) is shortened and the c-mos mRNA is degraded during early embryogenesis via EDEN (embryo deadenylation element) and EDEN-BP (EDEN-binding protein).
  • We cloned the full-length zebrafish c-mos gene, which is conserved at the protein coding region in vertebrates. c-mos mRNA has two putative CPE sequences in its 3'UTR, which binds to zebrafish CPEB homologous protein, Zor-1.
  • We could not observe EDEN sequence, and could not detect interaction between c-mos mRNA and zebrafish EDEN-BP homologous protein, Brul, even though immuno precipitation and RT-PCR experiments suggested that c-mos mRNA interacts with Zor-1 in vivo.
  • Interestingly, we found c-mos mRNA is located in the animal cortex of zebrafish oocyte, where Zor-1 protein exists.
  • [MeSH-major] Genes, mos / genetics. Oocytes / metabolism. RNA, Messenger / metabolism. RNA-Binding Proteins / metabolism. Zebrafish / embryology. Zebrafish Proteins / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Xenbase. Xenbase .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103830.001).
  • [ISSN] 1881-7823
  • [Journal-full-title] Bioscience trends
  • [ISO-abbreviation] Biosci Trends
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Zebrafish Proteins; 0 / zorba protein, zebrafish
  •  go-up   go-down


21. Raissi GR, Mokhtari A, Mansouri K: Reports from spinal cord injury patients: eight months after the 2003 earthquake in Bam, Iran. Am J Phys Med Rehabil; 2007 Nov;86(11):912-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The World Health Organization defines disaster as a sudden ecologic phenomenon of sufficient magnitude to require external assistance.
  • Fifty-two (96.3%) patients had pain syndromes, which had started from 3 days to 8 mos after injury.

  • MedlinePlus Health Information. consumer health - Disaster Preparation and Recovery.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049137.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Sakuma T, Hayashi Y, Kanomata N, Murayama T, Matsui T, Kajimoto K, Hanioka K, Chihara K, Maeda S: Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. Pathol Int; 2006 Apr;56(4):191-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
  • Bone marrow (BM) histology of 102 myelodysplastic syndromes (MDS) patients was analyzed retrospectively.
  • The cellularity in bone marrow histology is sometimes ineffective in the differential diagnosis of MDS and aplastic anemia (AA).
  • Nonetheless, a marked decrease in the number of megakaryocytes (average, 0.3/mm(2); range, 0-2/mm(2)) even in the hyperplastic foci of the marrow of AA was the most important histological feature differentiating AA from MDS, whereas the number of megakaryocytes increased in most MDS cases (44/mm(2); range, 1-240/mm(2)) and also in hypoplastic MDS (14/mm(2); range, 8-26/mm(2)).
  • Hyperplastic marrow had a significantly high frequency of progress to acute myeloid leukemia (AML) and hypoplastic MDS had a lower rate of progress to AML.
  • Severe myelofibrosis had a significantly poor prognosis.
  • [MeSH-major] Bone Marrow / pathology. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia, Aplastic / pathology. Cytogenetics. Diagnosis, Differential. Female. Humans. Leukemia / complications. Leukemia / epidemiology. Male. Middle Aged. Preleukemia / genetics. Preleukemia / mortality. Preleukemia / pathology. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate


23. Kiss A, Rosa RF, Dibi RP, Zen PR, Pfeil JN, Graziadio C, Paskulin GA: [Chromosomal abnormalities in couples with history of recurrent abortion]. Rev Bras Ginecol Obstet; 2009 Feb;31(2):68-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Anormalidades cromossômicas em casais com história de aborto recorrente.
  • PURPOSE: To asses the prevalence and clinical characteristics of couples with history of recurrent spontaneous abortion and chromosome abnormality, attended at the present service.
  • Clinical data on their age, as well as on the number of abortions, stillbirth, multiple malformations, livebirth per couple, and the result of the karyotype exam were collected.
  • In ten couples, one of the mates (9.3%) presented chromosome alterations, which corresponded respectively to three cases (30%) of reciprocal translocation [two of t(5;6) and one of t(2;13)], two (20%) of Robertsonian translocation [two of der(13;14) and one of der(13;15)], five(50%) of mosaicism (mos) [two cases of mos 45,X/46,XX, one of mos 46,XX/47,XXX, one of mos 46,XY/47,XXY and one of mos 46,XY/47,XYY] and one (10%) of chromosome inversion [inv(10)].
  • Chromosome abnormalities were found in 5% of the couples with a history of two abortions, in 10.3% with three abortions, and in 14.3% with four or more abortions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407911.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


24. Vannucchi AM, Guglielmelli P, Tefferi A: Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin; 2009 May-Jun;59(3):171-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in understanding and management of myeloproliferative neoplasms.
  • According to the 2008 World Health Organization classification system for hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, mastocytosis, chronic eosinophilic leukemia-not otherwise specified, chronic neutrophilic leukemia, and "MPN, unclassifiable."
  • In the last 4 years, new JAK2 and MPL mutations have been added to previously described ABL and KIT mutations as molecular markers of disease in MPN.
  • These discoveries have markedly simplified the approach to clinical diagnosis and have also provided molecular targets for the development of small-molecule drugs.
  • In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular pathogenesis, classification, diagnosis, and management.
  • [MeSH-major] Biomarkers, Tumor. Janus Kinase 2. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Receptors, Thrombopoietin

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society, Inc.
  • (PMID = 19369682.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 256
  •  go-up   go-down


25. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W: Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci; 2006 Dec;63(24):2939-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic mechanisms in myeloproliferative disorders.
  • Myeloproliferative disorders (MPDs) are clonal haematopoietic malignancies involving the abnormal proliferation of myeloid lineages.
  • The World Health Organisation (WHO) classification of haematopoietic malignancies distinguishes MPDs from myelodysplastic/ myeloproliferative disorders and systemic mastocytosis.
  • Chronic myelogenous leukaemia is the model used for studies of the consequences of such molecular defects.
  • This review focuses on the various tyrosine kinase-related molecular mechanisms underlying both MPDs and rare diseases with myeloproliferative features.
  • We pay particular attention to the newly identified JAK2 V617F mutation in polycythaemia vera, essential thrombocythaemia and idiopathic myelofibrosis and deal with disease heterogeneity and putative additional molecular mechanisms.
  • [MeSH-major] Genes, abl. Myeloproliferative Disorders / genetics. Protein-Tyrosine Kinases / genetics. Signal Transduction
  • [MeSH-minor] Genetic Predisposition to Disease. Humans. Janus Kinase 2 / genetics. Janus Kinase 2 / metabolism. Mastocytosis / genetics. Point Mutation. Proto-Oncogene Proteins c-kit / genetics. Rare Diseases / genetics. Rare Diseases / metabolism. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. mRNA Cleavage and Polyadenylation Factors / genetics

  • Guide to Pharmacology. gene/protein/disease-specific - Janus kinase (JakA) family - overview and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131059.001).
  • [ISSN] 1420-682X
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / FIP1L1 protein, human; 0 / mRNA Cleavage and Polyadenylation Factors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 131
  •  go-up   go-down


26. Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P: Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Hum Pathol; 2006 Nov;37(11):1458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
  • A retrospective investigation of the JAK2 V617F mutation was carried out in DNA samples from 131 bone marrow (BM) core biopsy specimens corresponding to patients with polycythemia vera (PV) (n = 31), essential thrombocythemia (ET) (n = 31), chronic idiopathic myelofibrosis (CIM) (n = 18), as well as patients with normal BM and secondary reactive hyperplasia.
  • [MeSH-major] Bone Marrow / chemistry. Janus Kinase 2 / genetics. Myeloproliferative Disorders / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Point Mutation. Polycythemia Vera / genetics. Polymerase Chain Reaction. Primary Myelofibrosis / genetics. Retrospective Studies. Thrombocythemia, Essential / genetics

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2007 Oct;38(10):1581-2 [17889678.001]
  • (PMID = 16949922.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


27. Bahr S, Borodin A, Höfft O, Kempter V, Allouche A: Interaction of formic acid with solid water. J Chem Phys; 2005 Jun 15;122(23):234704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastable impact electron spectroscopy and ultraviolet photoemission spectroscopy (He I and II) were utilized to study the electron emission from the 10a' to 6a' molecular orbitals (MOs) of FA, and the 1b(1), 3a(1), and 1b(2) MOs of H(2)O.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008470.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Linardi Cda C, Pracchia LF, Buccheri V: Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution. Sao Paulo Med J; 2008 Jan 2;126(1):52-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution.
  • CONTEXT AND OBJECTIVE: Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by predominant proliferation of erythroid precursors.
  • The aim of this study was to describe clinical and demographic characteristics of PV patients at diagnosis and analyze their long-term outcomes.
  • DESIGN AND SETTING: Retrospective study at the Division of Hematology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo.
  • Clinical and demographic characteristics, thrombotic events, transformation to acute leukemia, myelofibrosis and survival were evaluated.
  • Thirty-six (54.5%) were females, with a median age at diagnosis of 61 years.
  • At diagnosis, the median hemoglobin concentration was 18.8 mg/dl and the median platelet count was 593,000/mm(3).
  • The overall incidence of leukemia and myelofibrosis was 0.42% per patient-year and 1.06% per patient-year, respectively.
  • [MeSH-major] Polycythemia Vera / diagnosis. Polycythemia Vera / therapy

  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425288.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


29. Park D, Xiong YL, Alderton AL, Ooizumi T: Biochemical changes in myofibrillar protein isolates exposed to three oxidizing systems. J Agric Food Chem; 2006 Jun 14;54(12):4445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidation was induced by incubating the protein suspension at 4 degrees C for 24 h with (i) a hydroxyl radical-generating system (HRGS: 10 microM FeCl3, 0.1 mM ascorbic acid, and 0.05-5.0 mM H2O2), (ii) a lipid-oxidizing system (LOS: 0.05-5.0 mM linoleic acid and 3750 units of lipoxidase/mL), or (iii) a metmyoglobin-oxidizing system (MOS: 0.05-0.5 mM metmyoglobin).
  • The carbonyl content in MOS-treated MPI was the highest, while the TBARS production, changes in thermal properties, and loss of the myosin heavy chain were the greatest in HRGS-treated MPIs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756379.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Muscle Proteins; 0 / Thiobarbituric Acid Reactive Substances; 12772-23-5 / Metmyoglobin; 3352-57-6 / Hydroxyl Radical; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.4.1 / Myosin Heavy Chains; EC 3.6.4.1 / Myosins; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


30. Tan YQ, Di YF, Song YZ, Cheng DH, Li LY, Lu GX: [Delineating a supernumerary marker chromosome by combining several cytogenetic and molecular cytogenetic techniques]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug;24(4):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To characterize a supernumerary marker chromosome (SMC) by comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH) and traditional cytogenetic techniques, and to explore the clinical application of these techniques in delineating de novo marker chromosomes.
  • CGH and FISH techniques were used to analyze the origin of the de novo SMC, and N banding technique and C banding techniques were used to analyze the SMC structure.
  • RESULTS: By G banding technique, the patient was showed to have a mosaic karyotype with SMC: mos.47, XX, +mar [31]/48, XX, +2mar[29].
  • CGH analysis showed a gain of 15q11 --> q14, and the result was confirmed by FISH with chromosome 15 painting probe.
  • Combined with the above results, the karyotype of the patient was: mos.47, XX, +der (15) (pter --> q14::q14 --> pter) [31]/48, XX, +2der (15) (pter --> q14::q14 --> pter) [29].
  • Combined with FISH and the traditional cytogenetic technique, it provides a valuable technique platform for characterizing the structure of the de novo SMC, and a basis for exploring the relation between karyotype and phenotype, prognosis and recurrent risk.
  • [MeSH-minor] Chromosome Banding. Comparative Genomic Hybridization. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Intellectual Disability / diagnosis. Intellectual Disability / genetics. Karyotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680527.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. González-Viejo MA, Avellanet M, Hernández-Morcuende MI: [A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment]. Ann Readapt Med Phys; 2005 Nov;48(8):610-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Etude comparative dans traitement de la fibromyalgie: ultrasons et kinésithérapie versus sertraline.
  • Variables analyzed on a visual 10-point scale were pain and morning stiffness and sleep disorders by use of the sleep questionnaire of the Medical Outcome Study (MOS).
  • Morning stiffness and sleep disorder scores were positive only for the sertraline group during the entire 6 months (P<0.05).
  • Results from the MOS questionnaire showed improvement only for the sertraline group.

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • Hazardous Substances Data Bank. SERTRALINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979192.001).
  • [ISSN] 0168-6054
  • [Journal-full-title] Annales de réadaptation et de médecine physique : revue scientifique de la Société française de rééducation fonctionnelle de réadaptation et de médecine physique
  • [ISO-abbreviation] Ann Readapt Med Phys
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; QUC7NX6WMB / Sertraline
  •  go-up   go-down


32. Hogan BM, Verkade H, Lieschke GJ, Heath JK: Manipulation of gene expression during zebrafish embryonic development using transient approaches. Methods Mol Biol; 2008;469:273-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient disruption of the normal function of a gene during development can be achieved by microinjecting mRNA, DNA or short chemically stabilized anti-sense oligomers, called morpholinos (MOs), into early zebrafish embryos.
  • This chapter describes the most common and versatile approaches: gain of function and loss of function using DNA and mRNA injections and loss of function using MOs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109716.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Wnt Proteins; 0 / Zebrafish Proteins
  •  go-up   go-down


33. Gleason EJ, Lindsey WC, Kroft TL, Singson AW, L'hernault SW: spe-10 encodes a DHHC-CRD zinc-finger membrane protein required for endoplasmic reticulum/Golgi membrane morphogenesis during Caenorhabditis elegans spermatogenesis. Genetics; 2006 Jan;172(1):145-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C. elegans spermatogenesis employs lysosome-related fibrous body-membranous organelles (FB-MOs) for transport of many cellular components.
  • Previous work showed that spe-10 mutants contain FB-MOs that prematurely disassemble, resulting in defective transport of FB components into developing spermatids.
  • An antiserum to SPE-10 showed significant colocalization with a known marker for the FB-MOs during wild-type spermatogenesis.
  • The spe-10(eb64) missense mutation, which changes a conserved residue within the DHHC-CRD domain in all homologues, behaves as a null mutant.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1986 May;102(5):1787-96 [3517007.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):605-16 [11030340.001]
  • [Cites] Genetics. 1988 Oct;120(2):435-52 [3197956.001]
  • [Cites] Dev Biol. 1989 Aug;134(2):307-16 [2744235.001]
  • [Cites] J Immunol Methods. 1989 Dec 20;125(1-2):279-85 [2558138.001]
  • [Cites] EMBO J. 1992 May;11(5):1773-84 [1316273.001]
  • [Cites] J Cell Biol. 1992 Oct;119(1):55-68 [1527173.001]
  • [Cites] Genetics. 1993 Jan;133(1):79-86 [8417991.001]
  • [Cites] Science. 1994 Feb 11;263(5148):802-5 [8303295.001]
  • [Cites] Methods Cell Biol. 1995;48:365-94 [8531735.001]
  • [Cites] Int Rev Cytol. 2001;202:1-34 [11061562.001]
  • [Cites] Biochem J. 2001 Apr 15;355(Pt 2):249-58 [11284710.001]
  • [Cites] J Cell Biol. 2002 May 13;157(4):591-602 [12011109.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 16;296(2):492-6 [12163046.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):23-8 [12370247.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2815-28 [12393793.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41268-73 [12193598.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):1-34 [12459250.001]
  • [Cites] Genetics. 2003 Sep;165(1):145-57 [14504223.001]
  • [Cites] Cytometry. 1996 Jan 1;23(1):48-53 [14650440.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D138-41 [14681378.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D142-4 [14681379.001]
  • [Cites] Development. 1996 Jan;122(1):391-404 [8565851.001]
  • [Cites] Genetics. 1988 Jan;118(1):49-59 [8608931.001]
  • [Cites] Dev Biol. 1996 May 25;176(1):1-16 [8654886.001]
  • [Cites] Genetics. 1997 May;146(1):227-38 [9136012.001]
  • [Cites] Annu Rev Biochem. 2004;73:559-87 [15189153.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W20-5 [15215342.001]
  • [Cites] J Neurosci. 2004 Jun 30;24(26):5881-91 [15229235.001]
  • [Cites] Annu Rev Biochem. 1972;41:673-702 [4563441.001]
  • [Cites] Genetics. 1974 May;77(1):71-94 [4366476.001]
  • [Cites] Dev Biol. 1976 Mar;49(1):200-19 [943344.001]
  • [Cites] Dev Biol. 1976 Mar;49(1):220-35 [943345.001]
  • [Cites] Genetics. 1978 Feb;88(2):285-303 [580424.001]
  • [Cites] J Ultrastruct Res. 1978 May;63(2):155-69 [671581.001]
  • [Cites] Dev Biol. 1978 Oct;66(2):386-409 [700253.001]
  • [Cites] Mol Gen Genet. 1979 Sep;175(2):129-33 [292825.001]
  • [Cites] J Cell Biol. 1981 Oct;91(1):26-44 [7298721.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):203-8 [7049792.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • [Cites] Mol Immunol. 1983 Apr;20(4):483-9 [6191210.001]
  • [Cites] Dev Biol. 1984 Nov;106(1):223-35 [6541600.001]
  • [Cites] J Neurosci. 1985 Mar;5(3):643-53 [3882896.001]
  • [Cites] Genetics. 1985 May;110(1):17-72 [3996896.001]
  • [Cites] Cell. 1997 May 2;89(3):477-86 [9150147.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2464-9 [9171100.001]
  • [Cites] Genetics. 1997 Jun;146(2):567-81 [9178007.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Development. 1998 Jun;125(11):2087-98 [9570773.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5857-64 [9600884.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):854 [9804418.001]
  • [Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3645-54 [9819355.001]
  • [Cites] Development. 1999 May;126(10):2241-51 [10207148.001]
  • [Cites] Mol Cell Biochem. 1999 May;195(1-2):219-26 [10395086.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6775-87 [10490616.001]
  • [Cites] Neuron. 2004 Dec 16;44(6):977-86 [15603740.001]
  • [Cites] Neuron. 2004 Dec 16;44(6):987-96 [15603741.001]
  • [Cites] Dev Biol. 1981 Jun;84(2):299-312 [20737868.001]
  • [Cites] J Mol Biol. 2000 Feb 4;295(5):1103-12 [10653689.001]
  • [Cites] Mech Dev. 2000 Mar 1;91(1-2):5-17 [10704826.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2000;29:183-212 [10940247.001]
  • [Cites] Genetics. 1987 Jan;115(1):107-19 [3557107.001]
  • (PMID = 16143610.001).
  • [ISSN] 0016-6731
  • [Journal-full-title] Genetics
  • [ISO-abbreviation] Genetics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM040697; United States / NIGMS NIH HHS / GM / GM40697
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Immunoglobulin G; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC1456142
  •  go-up   go-down


34. Rao S, Kar R, Pati HP, Saxena R: Scleredema-associated IgA myeloma with myelofibrosis in a young adult: a case report. Turk J Haematol; 2008 Dec 5;25(4):195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scleredema-associated IgA myeloma with myelofibrosis in a young adult: a case report.
  • Scleredema of Buschke is a rare fibromucinous connective tissue disorder of unknown etiology.
  • It is often associated with a benign monoclonal gammopathy and rarely with myelomatosis.
  • We report a case of scleredema-associated IgA myeloma with myelofibrosis in a 24-year-old male patient.
  • Although mucin deposition in the bone marrow has been reported in scleredema, to the best of our knowledge, myelofibrosis has not been reported.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264923.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


35. Shalit P, True A, Thommes JA, QUALITE Investigators: Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials; 2007 Jan-Feb;8(1):24-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study.
  • Patients self-administered enfuvirtide, 90 mg bid, using thin-walled, 31-gauge/8-mm needles in combination with other ARvs. QoL was evaluated with MOS-HIV.
  • Although no baseline factors were predictive of week 12 QoL improvement, 9 of 11 MOS-HIV domain scores improved significantly, including physical function (p = .0002) and mental health (p = .0006).

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434846.001).
  • [ISSN] 1528-4336
  • [Journal-full-title] HIV clinical trials
  • [ISO-abbreviation] HIV Clin Trials
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / HIV Envelope Protein gp41; 0 / HIV Fusion Inhibitors; 0 / Peptide Fragments; 19OWO1T3ZE / enfuvirtide
  •  go-up   go-down


36. Sussner P, Valle ME: Gray-scale morphological associative memories. IEEE Trans Neural Netw; 2006 May;17(3):559-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus far, the emphasis in research on morphological associative memory systems has been on binary models, although a number of notable features of autoassociative morphological memories (AMMs) such as optimal absolute storage capacity and one-step convergence have been shown to hold in the general, gray-scale setting.
  • Specifically, we provide a complete characterization of the fixed points and basins of attractions which allows us to describe the storage and recall mechanisms of gray-scale AMMs.
  • Finally, we introduce a modified gray-scale AMM model that yields a fixed point which is closest to the input pattern with respect to the Chebyshev distance and show how gray-scale AMMs can be used as classifiers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722162.001).
  • [ISSN] 1045-9227
  • [Journal-full-title] IEEE transactions on neural networks
  • [ISO-abbreviation] IEEE Trans Neural Netw
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Jabbour E, Verstovsek S: Treatment of myelofibrosis in younger patients: to transplant or not? Am J Hematol; 2009 Mar;84(3):131-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of myelofibrosis in younger patients: to transplant or not?
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Janus Kinase 2 / antagonists & inhibitors. Janus Kinase 2 / genetics. Polymorphism, Single Nucleotide / genetics. Primary Myelofibrosis / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202548.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


38. Fitzpatrick EM, Durieux-Smith A, Whittingham J: Clinical practice for children with mild bilateral and unilateral hearing loss. Ear Hear; 2010 Jun;31(3):392-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: This population-based study consisted of a detailed retrospective chart review of all children identified with mild bilateral or unilateral hearing loss in a Canadian pediatric center between 1990 and 2006.
  • Clinical decisions regarding amplification practices were explored as a function of age of identification and severity of hearing loss.
  • RESULTS: A total of 670 children were identified with permanent hearing loss during the 16-yr study period, of which 291 were presented with a mild bilateral or unilateral hearing loss.
  • Detailed reviews of the 255 available medical charts showed that at diagnosis, 178 children presented with mild bilateral, 31 with mild bilateral high frequency, and 46 with unilateral hearing loss.
  • The average age of identification for the entire group was 54.2 mos (interquartile range, 30.1 to 76.9 mos).
  • Overall, 54.1% received an initial recommendation for amplification and a further 37.3% received a recommendation more than 3 mos after hearing loss confirmation.

  • MedlinePlus Health Information. consumer health - Hearing Aids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054278.001).
  • [ISSN] 1538-4667
  • [Journal-full-title] Ear and hearing
  • [ISO-abbreviation] Ear Hear
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C: MPL W515L mutation in Chinese patients with myeloproliferative diseases. Leuk Lymphoma; 2008 May;49(5):955-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MPL W515L mutation in Chinese patients with myeloproliferative diseases.
  • As JAK2 V617F, MPL W515L is a novel acquired mutation that induces constitutive cytokine-independent activation of the JAK-STAT pathway in myeloproliferative disorders (MPD).
  • MPL W515L mutation was found to be harbored in only one of 102 patients, who had essential thrombocythemia (ET, 1.0%) and was not detected in patients with polycythemia vera (PV), idiopathic myelofibrosis (IMF), and chronic myelogenous leukemia (CML).
  • Furthermore, MPL W515L and JAK2 V617F mutations were not detected in patients of acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and CML.
  • It has been shown that MPL W515L mutations may contribute to the primary molecular pathogenesis of Chinese patients with ET.
  • [MeSH-major] Mutation, Missense. Myeloproliferative Disorders / genetics. Receptors, Thrombopoietin / genetics
  • [MeSH-minor] Asian Continental Ancestry Group. Humans. Janus Kinase 2 / genetics. Polycythemia Vera. Primary Myelofibrosis. Thrombocythemia, Essential

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464114.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


40. Sambani C, La Starza R, Pierini V, Vandenberghe P, Gonzales-Aguilera JJ, Rigana H, Koumbi D, Manola KN, Stavropoulou C, Georgakakos VN, Pagoni M, Wlodarska I, Mecucci C: Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genet Cytogenet; 2005 Oct 1;162(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9).
  • We studied two patients with PV and one with idiopathic myelofibrosis bearing an unbalanced t(1;9) and one patient with essential thrombocythemia with a balanced t(1;9).
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 9. Myeloproliferative Disorders / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157199.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Nishimura Y, Endo T, Kano K, Naito K: Porcine Aurora A accelerates Cyclin B and Mos synthesis and promotes meiotic resumption of porcine oocytes. Anim Reprod Sci; 2009 Jul;113(1-4):114-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porcine Aurora A accelerates Cyclin B and Mos synthesis and promotes meiotic resumption of porcine oocytes.
  • Therefore we constructed a mutated Aurora A (AA-Aurora A), which was replaced the expecting inhibitory phosphorylation sites, serines 283 and 284, to non-phosphorylatable alanines.
  • The oocytes expressed AA-Aurora A were accelerated their Cyclin B synthesis and Rsk phosphorylation, an indicator of Mos synthesis, then their meiotic resumption was promoted significantly.
  • [MeSH-major] Cyclin B / biosynthesis. Meiosis / genetics. Oocytes / physiology. Protein-Serine-Threonine Kinases / physiology. Proto-Oncogene Proteins c-mos / biosynthesis. Sus scrofa


42. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant; 2007 Mar;13(3):355-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
  • A total of 104 patients, aged 18 to 70 years, with a diagnosis of chronic idiopathic myelofibrosis (CIMF), polycythemia vera (PV), or essential thrombocythemia (ET) with marrow fibrosis were transplanted from allogeneic (56 related and 45 unrelated) or syngeneic (n = 3) donors.
  • Busulfan (BU) or total body irradiation (TBI)-based myeloablative conditioning regimens were used in 95 patients, and a nonmyeloablative regimen of fludarabine plus TBI was used in 9 patients.
  • The source of stem cells was bone marrow in 43 patients and peripheral blood in 61 patients.
  • Eleven patients had recurrent/persistent disease, of whom 8 died.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Polycythemia Vera / therapy. Primary Myelofibrosis / therapy. Thrombocythemia, Essential / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Female. Humans. Male. Middle Aged. Models, Statistical. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Transplantation, Isogeneic


43. Rodriguez JA, Liu P, Takahashi Y, Nakamura K, Viñes F, Illas F: Desulfurization of thiophene on Au/TiC(001): Au-C interactions and charge polarization. J Am Chem Soc; 2009 Jun 24;131(24):8595-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of the very poor desulfurization performance of TiC(001) or Au(111), a Au/TiC(001) system displays a hydrodesulfurization activity higher than that of conventional Ni/MoS(x) catalysts.
  • The Au<-->TiC(001) interactions induce a polarization of electron density around Au which substantially increases the chemical reactivity of this metal.
  • Thiophene binds in a eta(5) configuration with a large elongation (approximately 0.2 A) of the C-S bonds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530731.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Tivanski AV, Walker GC: Ferrocenylundecanethiol self-assembled monolayer charging correlates with negative differential resistance measured by conducting probe atomic force microscopy. J Am Chem Soc; 2005 May 25;127(20):7647-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrical and mechanical properties of metal-molecule-metal junctions formed between Au-supported self-assembled monolayers (SAMs) of electroactive 11-ferrocenylundecanethiol (FcC(11)SH) and a Pt-coated atomic force microscope (AFM) tip have been measured using a conducting probe (CP) AFM in insulating alkane solution.
  • A mechanism involving two-step resonant hole transfer through the occupied molecular orbitals (MOs) of ferrocene end groups via sequential oxidation and subsequent reduction, where a hole is trapped by the phonon relaxation, is proposed to explain the observed current-force correlation.
  • These results suggest a new approach to probe charge-transfer involving electroactive groups on the nanoscale by measuring the adhesion forces as a function of applied bias in an electrolyte-free environment.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898817.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP: Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol; 2009 May;84(5):265-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
  • Serum ferritin level at diagnosis was available in 185 patients with primary myelofibrosis (PMF); twenty-two (12%) patients had serum ferritin >1,000 ng/mL and 32 (17%) were red blood cell (RBC) transfusion-dependent.
  • On multivariable analysis that included age as a covariate, RBC transfusion need at diagnosis (P < 0.0001), but not increased serum ferritin or transfusion load, predicted shortened survival.
  • In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value.
  • [MeSH-major] Erythrocyte Transfusion. Ferritins / blood. Primary Myelofibrosis / blood. Primary Myelofibrosis / therapy

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396855.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-73-2 / Ferritins
  •  go-up   go-down


46. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica; 2005 Aug;90(8):1128-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European consensus on grading bone marrow fibrosis and assessment of cellularity.
  • Quantification of characteristic bone marrow biopsy features includes basic parameters such as cellularity and fiber content.
  • These are important to assess the dynamics of disease processes with a significant impact on risk stratification, survival patterns and, especially, therapy-related changes.
  • A panel of experienced European pathologists and a foreign expert evaluated, at a multi-headed microscope, a large number of representative slides of trephine biopsies from patients with myelofibrosis in an attempt to reach a consensus on how to grade cellularity and fibrosis.
  • Grading of myelofibrosis was simplified by using four easily reproducible categories including differentiation between reticulin and collagen.
  • This feature is especially important in order to avoid a false impression of a reduced fiber content in fatty and/or edematous bone marrow samples after treatment.
  • The consensus for measuring myelofibrosis by clear and reproducible guidelines achieved by our group should allow for precise grading during the disease process and after therapy.
  • [MeSH-major] Bone Marrow / pathology. Primary Myelofibrosis / pathology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079113.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


47. Bulakbaşı Balcı T, Yüksel M, Yılmaz Z, Şahin Fİ: Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient. Turk J Haematol; 2010 Jun 5;27(2):113-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient.
  • Chronic idiopathic myelofibrosis is a myeloproliferative disorder characterized by splenomegaly, myeloid metaplasia and reactive bone marrow fibrosis.
  • Karyotype analysis of the bone marrow is an integral part of the diagnosis, especially as a discriminative tool in ruling out reactive conditions.
  • The frequency of clonal cytogenetic anomalies in this disease is the highest among its group, varying between 30 and 75%.
  • Here we report a 66-year-old male patient whose bone marrow biopsy revealed signs of chronic myeloproliferative changes and dysmegakaryopoiesis.
  • The patient worsened in the following months and the second bone marrow biopsy revealed myelofibrosis.
  • Cytogenetic analysis of this bone marrow sample revealed a complex karyotype reported to be 46,XY,del(9)(q22q34),t(8;17;21)(q22;q21;q22)[23]/46,XY[2], with a previously undefined three-way translocation and deletion in chromosome 9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27263453.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


48. Shao J, Shi R, Wang C, Zhu X, Lu X: Exploration of structure, potential energy surface, and stability of planar C3B3. J Mol Model; 2010 May;16(5):939-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, isomers 1 (C(s),(2)A') and 2 (C(s),(2)A'), with a belt-like structure corresponding to the lowest-energy structures of planar C(3)B(3), are revealed.
  • Based on molecular orbital (MO) and natural bond orbital (NBO) analyses, delocalized sigma MOs, multi-centered sigma MOs, and delocalized pi MOs play an important role in stabilizing the structures of low-energy isomers of C(3)B(3).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2007 Jul;67(3-4):756-61 [17023194.001]
  • [Cites] J Am Chem Soc. 2004 Oct 27;126(42):13845-9 [15493945.001]
  • [Cites] Science. 2000 Dec 8;290(5498):1937-40 [11110655.001]
  • [Cites] J Phys Chem A. 2009 Nov 12;113(45):12404-10 [19888773.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2005 Nov;62(1-3):596-603 [16257764.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2007 Jan;66(1):153-62 [17010663.001]
  • [Cites] J Phys Chem A. 2009 Apr 9;113(14):3382-6 [19296637.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 Nov;22(22):3599-607 [18937227.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(38):7164-7 [18683843.001]
  • [Cites] Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789 [9944570.001]
  • [Cites] J Am Chem Soc. 2008 Feb 27;130(8):2580-92 [18237168.001]
  • [Cites] J Phys Chem A. 2007 Feb 1;111(4):704-9 [17249761.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2005 Sep;61(11-12):2730-6 [16043071.001]
  • [Cites] J Phys Chem A. 2006 Jan 26;110(3):908-12 [16419988.001]
  • [Cites] Science. 2001 Jun 29;292(5526):2465-9 [11431561.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2007 Feb;66(2):512-20 [16872866.001]
  • [Cites] J Chem Phys. 2004 May 15;120(19):8985-95 [15267834.001]
  • [Cites] J Am Chem Soc. 2003 Nov 5;125(44):13318-9 [14583002.001]
  • (PMID = 19834747.001).
  • [ISSN] 0948-5023
  • [Journal-full-title] Journal of molecular modeling
  • [ISO-abbreviation] J Mol Model
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


49. Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH: Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer; 2006 Jan 15;106(2):361-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced biliary tract carcinomas (BTCs) are associated with a very poor prognosis.
  • New therapeutic strategies therefore are needed to improve efficacy and survival, and the current study was designed with a new, effective drug combination.
  • Seventeen patients achieved a partial response (40%; 95% confidence interval [95% CI], 21-49%) and 10 had stable disease.
  • With a follow-up duration of 18 months, the median survival time was 8 months (95% CI, 6-10 mos).
  • In total, 187 chemotherapy cycles were delivered, with a median of 5 cycles per patient (range, 1-9 cycles).

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342166.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood; 2008 Jan 01;111(1):60-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
  • The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and there has been little attempt to quantitate interobserver variability.
  • Diagnostic bone marrow trephine biopsy specimens from 370 patients with ET by Polycythemia Vera Study Group (PVSG) criteria were assessed by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to the World Health Organization (WHO) classification.
  • Our results show substantial interobserver variability, particularly for overall diagnosis and individual cellular characteristics such as megakaryocyte morphology.
  • One factor related to overall and lineage-specific cellularity and was significantly associated with JAK2 V617F status (P < .001), a second factor related to megakaryocyte clustering, and a third was associated with the fibrotic process.
  • No differences could be discerned between patients labeled as having "prefibrotic myelofibrosis" or "true ET" in clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation.
  • These results show that histologic criteria described in the WHO classification are difficult to apply reproducibly and question the validity of distinguishing true ET from prefibrotic myelofibrosis on the basis of subjective morphologic criteria.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Aspirin / therapeutic use. Biopsy. Blood Cell Count. Drug Therapy, Combination. Humans. Hydroxyurea / therapeutic use. Megakaryocytes / pathology. Observer Variation. Platelet Aggregation Inhibitors / therapeutic use. Primary Myelofibrosis / classification. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / pathology. Prospective Studies. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885079.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN72251782
  • [Grant] United Kingdom / Wellcome Trust / / 088340; United Kingdom / Cancer Research UK / / 8961; United Kingdom / Medical Research Council / / G0300497
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platelet Aggregation Inhibitors; 0 / Quinazolines; K9X45X0051 / anagrelide; R16CO5Y76E / Aspirin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


51. Schroeder SL, Weiher N: F K-edge X-ray absorption near-edge structure (XANES) of AlF3 polymorphs: combining ab initio calculations with Walsh correlation diagrams. Phys Chem Chem Phys; 2006 Apr 21;8(15):1807-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The X-ray absorption near-edge structures (XANES) at the F K-edge of alpha-AlF(3), beta-AlF(3) and a tetragonal AlF(3) phase are analysed by a combination of ab initio calculations with the FEFF8 code and a phenomenological discussion of local molecular orbital (MO) symmetries at the absorbing fluorine atoms.
  • By means of a Walsh correlation diagram it is shown that the two intense absorption bands observed at the F K-edges of the AlF(3) polymorphs can be interpreted as transitions to anti-bonding MOs in [Al-F-Al]-units that have C(2v) and D(infinity h) point group symmetries.
  • The interpretation in terms of local MOs provides for the first time a "chemically intuitive" approach to investigations of solid fluorides by XANES spectroscopy and provides a simple conceptual framework for the discussion of the electronic structure in AlF(3) materials.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM FLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633665.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Ions; 0 / Macromolecular Substances; Q80VPU408O / Fluorides; Z77H3IKW94 / aluminum fluoride
  •  go-up   go-down


52. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, Ibatici A, Raiola AM, Frassoni F, De Stefano F, Verdiani S, Casarino L, Barosi G: Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant; 2010 Mar;45(3):458-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
  • A total of 46 patients with primary myelofibrosis (PMF) (median age 51 years), underwent an allogeneic hemopoietic SCT (HSCT) after a thiotepa-based reduced-intensity conditioning regimen.
  • The actuarial survival of low-risk and high-risk patients is, respectively, 77 and 8% (P<0.0001); this is because of a higher TRM for high-risk patients (RR, 6.0, P=0.006) and a higher relapse-related death (RR, 7.69; P=0.001).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Primary Myelofibrosis / therapy

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2010 Mar;45(3):419-21 [20216545.001]
  • (PMID = 19718055.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN, Sorror M, Hoppe R, Maloney DG, Negrin RS, Shizuru JA, Sandmaier BM: Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transplant; 2009 Oct;15(10):1314-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grafts were rejected in 5 patients (13%), 4 of whom had myelofibrosis.
  • With a median follow-up of 2 years (range: 0.3 to 7.8 years), the 2- and 4-year estimated survivals were 49% and 42%, respectively.
  • The 2-year cumulative incidences of grades II-IV acute and moderate-severe chronic graft-versus-host disease (aGVHD, cGVHD) were 42% and 41%, respectively.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1620-9 [12393457.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2254-62 [15226174.001]
  • [Cites] N Engl J Med. 1975 Apr 17;292(16):832-43 [234595.001]
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(3):211-24 [2257085.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):304-13 [8426208.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3384-9 [8193376.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4376-81 [7492799.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3048-54 [9108426.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21(7):687-90 [9578308.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2303-14 [9746768.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2742-9 [9763558.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1131-6 [10419907.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Apr;15(4):483-9 [19285636.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Rev Invest Clin. 2006 Jan-Feb;58(1):34-8 [16789597.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65 [17317589.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):431-5 [17603511.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Nov;13(11):1313-23 [17950918.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):33-9 [17884640.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):39-43 [17982503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):523-8 [17869449.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55 [18215785.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):859-66 [18640568.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1298-304 [18940685.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • (PMID = 19747640.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029-34; United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA49605; United States / NCI NIH HHS / CA / P30 CA015704-35; United States / NCI NIH HHS / CA / CA078902-11; United States / NHLBI NIH HHS / HL / R00 HL088021; United States / NCI NIH HHS / CA / CA015704-35; United States / NHLBI NIH HHS / HL / HL088021-02; United States / NCI NIH HHS / CA / P01 CA078902-11; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / CA049605-20; United States / NHLBI NIH HHS / HL / K99 HL088021-02; United States / NHLBI NIH HHS / HL / HL036444-28; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NHLBI NIH HHS / HL / P01 HL036444-28; United States / NCI NIH HHS / CA / P01 CA078902; United States / NHLBI NIH HHS / HL / K99 HL088021; United States / NCI NIH HHS / CA / P01 CA049605-20; United States / NCI NIH HHS / CA / P01 CA049605; United States / NHLBI NIH HHS / HL / HL088021
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS128159; NLM/ PMC2757150
  •  go-up   go-down


54. Protopopescu C, Marcellin F, Spire B, Préau M, Verdon R, Peyramond D, Raffi F, Chêne G, Leport C, Carrieri MP: Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res; 2007 May;16(4):577-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analysed the HRQL evolution over 5 years for 1,000 patients initiating a protease inhibitor (PI)-containing therapy, using MOS SF-36 physical (PCS) and mental (MCS) scores.
  • In parallel with a classical separate random effects model, we used a joint parameter-dependent selection model to account for non-ignorable dropout.
  • RESULTS: HRQL evolved according to a two-phase pattern, characterized by an initial improvement during the year following HAART initiation and a relative stabilization thereafter.


55. Lathia KB, Yan Z, Clapshaw PA: Spinal cord transcriptome analysis using suppression subtractive hybridization and mirror orientation selection. Cell Mol Neurobiol; 2006 May;26(3):259-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2. The possibility that the subtraction process was simply overwhelmed by background sequences was significantly reduced by several observations including comparisons between suppression subtractive hybridization (SSH) and mirror orientation selection (MOS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 2001 Aug 10;910(1-2):29-37 [11489251.001]
  • [Cites] J Neurosci. 1994 Aug;14(8):4915-26 [8046460.001]
  • [Cites] Mol Cell Neurosci. 2001 Dec;18(6):593-605 [11749036.001]
  • [Cites] J Neurosci. 2002 Mar 1;22(5):1772-83 [11880506.001]
  • [Cites] Nucleic Acids Res. 2000 Oct 15;28(20):E90 [11024192.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):86-97 [11352569.001]
  • [Cites] Cell Mol Neurobiol. 2005 Mar;25(2):407-26 [16047549.001]
  • [Cites] J Mol Neurosci. 1991;3(2):59-64 [1687656.001]
  • [Cites] Nucleic Acids Res. 1983 Aug 25;11(16):5497-520 [6193485.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21264-70 [7673161.001]
  • [Cites] J Neurosci. 2006 Feb 1;26(5):1439-47 [16452667.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):55-63 [11978393.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1646-53 [12840043.001]
  • [Cites] Neuron. 2003 Apr 24;38(2):161-75 [12718852.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6025-30 [8650213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11038-43 [11005875.001]
  • [Cites] Neurochem Res. 1984 Jan;9(1):133-46 [6201756.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11709-13 [7526402.001]
  • [Cites] Neuron. 1997 Jan;18(1):59-70 [9010205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(19):6706-10 [3901006.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1610-3 [9616125.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Comp Neurol. 1998 May 18;394(4):506-19 [9590558.001]
  • (PMID = 16619132.001).
  • [ISSN] 0272-4340
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 63231-63-0 / RNA
  •  go-up   go-down


56. Moran GW, Fisher NC: Myelofibrosis, splenomegaly, and upper gastrointestinal hemorrhage: an unusual link. Clin Gastroenterol Hepatol; 2008 Sep;6(9):xxiv
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis, splenomegaly, and upper gastrointestinal hemorrhage: an unusual link.
  • [MeSH-major] Arteriovenous Fistula / diagnosis. Gastrointestinal Hemorrhage / complications. Primary Myelofibrosis / complications. Splenic Diseases / diagnosis. Splenomegaly / complications


57. Aydinok Y: Myelofibrosis in a child with EBV-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer; 2008 Aug;51(2):311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis in a child with EBV-associated hemophagocytic lymphohistiocytosis.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphohistiocytosis, Hemophagocytic / pathology. Primary Myelofibrosis / etiology


58. Lichtman MA: Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis. Blood; 2007 Oct 15;110(8):3085-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Megakaryocytes / pathology. Primary Myelofibrosis / pathology. Terminology as Topic
  • [MeSH-minor] Chronic Disease. Humans. Hyperplasia

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2007 Aug 1;110(3):986-93 [17473062.001]
  • (PMID = 17916755.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


59. Tefferi A, Dingli D, Li CY, Mesa RA: Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res; 2006 Jun;30(6):677-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.
  • It is also infrequently seen in "anemia of chronic disease" that accompanies a spectrum of chronic conditions including rheumatoid arthritis, polymyalgia rheumatica, diabetes mellitus, connective tissue disease, and protracted infection.
  • In addition, there is a well established but pathogenetically obscure association of microcytosis with Hodgkin's lymphoma, Castleman's disease, and renal cell carcinoma.
  • In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting.
  • [MeSH-major] Anemia, Macrocytic / mortality. Primary Myelofibrosis / mortality
  • [MeSH-minor] Adolescent. Adult. Anemia, Iron-Deficiency / complications. Anemia, Iron-Deficiency / mortality. Anemia, Iron-Deficiency / pathology. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / mortality. Giant Lymph Node Hyperplasia / pathology. Hodgkin Disease / complications. Hodgkin Disease / mortality. Hodgkin Disease / pathology. Humans. Male. Middle Aged. Prevalence. Thalassemia / complications. Thalassemia / mortality. Thalassemia / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288807.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Hernández C, Estivill E, Cantalapiedra A: [Impact of nocturia on sleep quality in patients with lower urinary tract symptoms suggesting benign prostatic hyperplasia (LUTS/BPH). The NocSu Study]. Actas Urol Esp; 2010 May;34(5):450-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Impacto de la nocturia en la calidad del sueño en pacientes con síntomas del tracto urinario inferior sugestivos de hiperplasia benigna de la próstata. Estudio NocSu.
  • In the study visit, demographic and clinical data were collected and quality of sleep questionnaires (MOS-Sleep Scale and COS) were administered.

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20470718.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


61. Yamashiro S, Nishi T, Koga K, Kaji M, Goto T, Muta D, Fujioka S, Kuratsu J: [Self-assesed quality of life in patients who underwent surgery for asymptomatic meningiomas]. No Shinkei Geka; 2007 Dec;35(12):1149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventeen patients participated in the QOL survey using MOS Short-Form 36-Item Health Survey (SF-36) for health-related QOL issues and the Hospital Anxiety and Depression Scale (HADS) for anxiety nd depression assessment.
  • The mean scores for each of the 8 domains of SF-36 were comparable with these of a Japanese reference population.
  • [MeSH-minor] Activities of Daily Living. Aged. Anxiety / diagnosis. Data Collection. Depression / diagnosis. Female. Headache / etiology. Humans. Male. Middle Aged. Postoperative Complications. Self-Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080514.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Tarkka IM, Pitkänen K, Sivenius J: Paretic hand rehabilitation with constraint-induced movement therapy after stroke. Am J Phys Med Rehabil; 2005 Jul;84(7):501-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the effectiveness of constraint-induced movement therapy in improving motor abilities in very chronic stroke subjects.
  • DESIGN: Participants were 27 consecutive chronic stroke subjects (mean age, 56 +/- 13 yrs) who fulfilled specific motor criteria.
  • The obtained improvements in the affected arm motor behavior endured for 5 mos after the therapy.
  • CONCLUSIONS: Chronic stroke subjects, who have sufficient residual motor control for exercise, benefit from highly concentrated therapy and can still enhance their voluntary motor control of the affected arm even years after the incident.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973086.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Jakobsen HJ, Hove AR, Bildsøe H, Skibsted J, Brorson M: Advancements in natural abundance solid-state 33S MAS NMR: characterization of transition-metal M=S bonds in ammonium tetrathiometallates. Chem Commun (Camb); 2007 Apr 28;(16):1629-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advancements in natural abundance solid-state 33S MAS NMR: characterization of transition-metal M=S bonds in ammonium tetrathiometallates.
  • We report the first (33)S chemical shift anisotropy (CSA) data as obtained from a combined determination of (33)S CSA and quadrupole coupling parameters utilizing the observation of both the (33)S (I = 3/2) central and satellite transitions in a natural abundance (33)S MAS NMR study aimed at characterizing the two important tetrathiometallates (NH4)(2)MoS(4) and (NH4)(2)WS(4).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530082.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Lin P, Smyth L, Waldram A, Henderson RA: Kinetics of the reactions between [S(2)MoS(2)Cu(SC(6)H(4)R-4)](2-)(R = MeO, H, Cl or NO(2)) and CN(-): substitution mechanism at a 3-coordinate Cu(I) site. Dalton Trans; 2005 Oct 7;(19):3173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of the reactions between [S(2)MoS(2)Cu(SC(6)H(4)R-4)](2-)(R = MeO, H, Cl or NO(2)) and CN(-): substitution mechanism at a 3-coordinate Cu(I) site.
  • The kinetics of the reaction between [S(2)MoS(2)Cu(SC(6)H(4)R-4)](2-)(R = MeO, H, Cl or NO(2)) and CN(-) to form [S(2)MoS(2)CuCN](2-) have been studied in MeCN using stopped-flow spectrophotometry.
  • In all cases, the rate law is of the form, Rate ={k+k(2)(R)[CN(-)]}[S(2)MoS(2)Cu(SC(6)H(4)R-4)(2-)].
  • The k pathway involves attack of the solvent (MeCN) at the copper site, followed by dissociation of the thiolate to form [S(2)MoS(2)Cu(NCMe)](-).
  • Subsequent rapid substitution of the coordinated solvent by cyanide produces [S(2)MoS(2)CuCN](2-).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172642.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Piccinni A, Maser JD, Bazzichi L, Rucci P, Vivarelli L, Del Debbio A, Catena M, Bombardieri S, Dell'Osso L: Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis. Compr Psychiatry; 2006 May-Jun;47(3):201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients met diagnostic criteria of RA according to the American College of Rheumatology.
  • Health-related quality of life was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey questionnaire (MOS SF-36).
  • RESULTS: Patients with RA were compared, as regards the MOS SF-36 scale scores, with the Italian normative population and patients with diabetes.
  • Compared with the Italian population, patients with RA showed significantly lower MOS SF-36 scale scores, except for role emotional.
  • A significant worsening of all MOS SF-36 scale scores was related to higher scores of the depressive domains of MOODS-SR, except for social functioning and bodily pain.
  • A statistically significant negative association was also found between PAS-SR total score and the MOS SF-36 scales physical functioning, vitality, role emotional, and mental health.
  • There were no statistically significant correlations between MOS SF-36 scales and the manic MOODS spectrum.
  • In the multivariate models, the negative correlations between depressive MOODS, role emotional, and mental health were confirmed and the severity of arthritis showed a significant impact on all MOS SF-36 areas with the exception for social functioning; moreover, manic MOODS was associated with better general health.
  • Diagnosis and appropriate clinical management of depression, including subthreshold symptoms, might enhance HRQoL in these patients.
  • [MeSH-major] Agoraphobia / psychology. Arthritis, Rheumatoid / psychology. Mood Disorders / psychology. Panic Disorder / psychology. Quality of Life


66. Tripodi J, Hoffman R, Najfeld V, Weinberg R: Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Manag Res; 2010 Sep 17;2:219-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.
  • The Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are a group of clonal hematopoietic stem cell disorders with overlapping clinical and cytogenetic features and a variable tendency to evolve into acute leukemia.
  • The goal of this study was to investigate the frequency of genomic TET2 rearrangements in MPN using fluorescence in situ hybridization as a more sensitive method for screening and identifying genomic deletions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188113.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108671
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004566
  • [Keywords] NOTNLM ; TET2 / cytogenetics / fluorescence in situ hybridization / myeloproliferative neoplasms
  •  go-up   go-down


67. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D: The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol; 2005 Nov;131(3):320-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
  • An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple simultaneous publications.
  • In the current study, mutation analysis for JAK2(V617F) was performed in peripheral blood mononuclear cells (PBMC) from 157 patients with myelofibrosis with myeloid metaplasia (MMM) including 117 with agnogenic (AMM), 22 with postpolycythaemic (PPMM), and 18 with post-thrombocythaemic (PTMM) myeloid metaplasia.
  • The detection rate for JAK2(V617F) was significantly higher in PPMM (91%; homozygous in 18%) compared with either AMM (45.3%; homozygous in 2.6%) or PTMM (38.9%; homozygous in 11.1%).
  • In AMM, the presence of JAK2(V617F) was associated with an older age at diagnosis and a history of thrombosis or pruritus.
  • In conclusion, JAK2(V617F) is a myeloid lineage-specific event, its incidence in MMM is significantly higher with an antecedent history of polycythaemia vera (PV), and its presence in AMM does not affect prognosis but is associated with PV-characteristic clinical features.
  • [MeSH-major] Mutation. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225651.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


68. Kim DY, Lim JY, Kang EK, You DS, Oh MK, Oh BM, Paik NJ: Effect of transcranial direct current stimulation on motor recovery in patients with subacute stroke. Am J Phys Med Rehabil; 2010 Nov;89(11):879-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blinded evaluators assessed upper limb motor impairment and global functional state with the Fugl-Meyer Assessment score and the Modified Barthel Index at baseline, 1 day after stimulation, and 6 mos after stimulation.
  • There was a significant inverse correlation between baseline Fugl-Meyer Assessment and Fugl-Meyer Assessment increase at 6 mos (r = -0.846; P < 0.01).

  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962598.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Nishiyama T, Ohsumi K, Kishimoto T: Phosphorylation of Erp1 by p90rsk is required for cytostatic factor arrest in Xenopus laevis eggs. Nature; 2007 Apr 26;446(7139):1096-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicate that Erp1/Emi2, an inhibitor protein for the APC/C, has an essential role in establishing and maintaining CSF arrest, but its relationship to Mos, a mitogen-activated protein kinase (MAPK) kinase kinase that also has an essential role in establishing CSF arrest through activation of p90 ribosomal S6 kinase (p90rsk), is unclear.
  • Here we report that in Xenopus eggs Erp1 is a substrate of p90rsk, and that Mos-dependent phosphorylation of Erp1 by p90rsk at Thr 336, Ser 342 and Ser 344 is crucial for both stabilizing Erp1 and establishing CSF arrest in meiosis II oocytes.
  • Semi-quantitative analysis with CSF-arrested egg extracts reveals that the Mos-dependent phosphorylation of Erp1 enhances, but does not generate, the activity of Erp1 that maintains metaphase arrest.
  • Our results also suggest that Erp1 inhibits cyclin B degradation by binding the APC/C at its carboxy-terminal destruction box, and this binding is also enhanced by the Mos-dependent phosphorylation.
  • Thus, Mos and Erp1 collaboratively establish and maintain metaphase II arrest in Xenopus eggs.
  • The link between Mos and Erp1 provides a molecular explanation for the integral mechanism of CSF arrest in unfertilized vertebrate eggs.
  • [MeSH-major] F-Box Proteins / metabolism. Oocytes / cytology. Oocytes / metabolism. Proto-Oncogene Proteins c-mos / metabolism. Ribosomal Protein S6 Kinases, 90-kDa / metabolism. Xenopus Proteins / metabolism. Xenopus laevis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410129.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Erp1 protein, Xenopus; 0 / F-Box Proteins; 0 / Xenopus Proteins; EC 2.7.11.1 / Proto-Oncogene Proteins c-mos; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 90-kDa; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


70. Vitale I, Senovilla L, Jemaà M, Michaud M, Galluzzi L, Kepp O, Nanty L, Criollo A, Rello-Varona S, Manic G, Métivier D, Vivet S, Tajeddine N, Joza N, Valent A, Castedo M, Kroemer G: Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J; 2010 Apr 7;29(7):1272-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos.
  • Here, we show that the absence of p53 is not only permissive for the survival but also for multipolar asymmetric divisions of tetraploid cells, which lead to the generation of aneuploid cells with a near-to-diploid chromosome content.
  • Multipolar mitoses (which reduce the tetraploid genome to a sub-tetraploid state) are more frequent when p53 is downregulated and the product of the Mos oncogene is upregulated.
  • Mos inhibits the coalescence of supernumerary centrosomes that allow for normal bipolar mitoses of tetraploid cells.
  • In the absence of p53, Mos knockdown prevents multipolar mitoses and exerts genome-stabilizing effects.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Genes, mos. Mitosis. Polyploidy. Tumor Suppressor Protein p53 / metabolism


71. Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A: Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol; 2005 Jul;130(2):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.
  • Chromosome anomalies are detected in approximately half of patients with myelofibrosis with myeloid metaplasia (MMM) although none of the most prevalent lesions are specific to the disease.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 6 / genetics. Primary Myelofibrosis / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029451.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


72. Oh ST, Gotlib J: JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol; 2010 Jun;3(3):323-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
  • Dysregulated signaling is a hallmark of chronic myeloproliferative neoplasms (MPNs), as evidenced by the identification of the activating JAK2 V617F somatic mutation in almost all patients with polycythemia vera (PV) and 50-60% of essential thrombocythemia and primary myelofibrosis patients.
  • These disorders are clinically distinct, raising the question of how a single mutation can result in such phenotypic diversity.
  • However, the molecular basis of JAK2 V617F-negative essential thrombocythemia and primary myelofibrosis remains largely unexplained.
  • Mutations in the TET2 gene have been identified in both JAK2 V617F-positive and -negative MPNs and other myeloid neoplasms, but their functional and clinical significance have yet to be clarified.
  • [MeSH-major] Janus Kinase 2. Mutation. Polycythemia Vera. Primary Myelofibrosis. Protein Kinase Inhibitors / administration & dosage. STAT Transcription Factors / metabolism. Signal Transduction / genetics. Thrombocythemia, Essential

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082983.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / STAT Transcription Factors; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


73. Miyata T, Masuzawa M, Katsuoka K, Higashihara M: Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis. J Dermatol; 2008 Jul;35(7):456-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis.
  • Idiopathic myelofibrosis (IM) is a chronic myeloproliferative disorder and some cases of IM have extramedullary hematopoiesis.
  • [MeSH-major] Hematopoiesis, Extramedullary. Primary Myelofibrosis / complications. Skin Diseases / etiology. Skin Diseases / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705835.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Lu Y, Huang Q: Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation. Leuk Lymphoma; 2009 Nov;50(11):1879-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Primary Myelofibrosis / surgery. Sarcoma, Myeloid / diagnosis. Stem Cell Transplantation / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Janus Kinase 2 / genetics. Male. Mutation. Recurrence. Transplantation, Homologous


75. Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D, Albrecht S: Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med; 2008 Dec;9(8):874-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our goal was to test the ability of pramipexole to improve sleep in RLS patients and to reconfirm its efficacy for primary RLS symptoms.
  • The co-primary outcome measures were change in Medical Outcomes Study (MOS) sleep disturbance score and International RLS Study Group Rating Scale (IRLS) score at 12 weeks.
  • At 12 weeks, the adjusted mean change from baseline was greater for pramipexole (vs. placebo) for IRLS score (-13.4+/-0.7 vs. -9.6+/-0.7) and MOS sleep disturbance score (-25.3+/-1.5 vs. -16.8+/-1.5) (p<or=0.0001; ANCOVA).
  • RLS-QOL score was improved over placebo at Week 12 (p<0.01) as were MOS sleep adequacy (p=0.0008) and quantity (p=0.08) scores.

  • MedlinePlus Health Information. consumer health - Restless Legs.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952497.001).
  • [ISSN] 1389-9457
  • [Journal-full-title] Sleep medicine
  • [ISO-abbreviation] Sleep Med.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzothiazoles; 0 / Dopamine Agonists; 83619PEU5T / pramipexole
  •  go-up   go-down


76. Stölzel F, Babatz J, Thiede C, Siegert G, Illmer T, Ehninger G, Schaich M: Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation. Ann Hematol; 2008 Dec;87(12):1021-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation.
  • [MeSH-major] Calcitonin / blood. Fever / genetics. Janus Kinase 2 / genetics. Mutation / genetics. Primary Myelofibrosis / genetics. Protein Precursors / blood

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548249.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 56645-65-9 / procalcitonin; 9007-12-9 / Calcitonin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


77. Alvarez-Hernández E, Zamudio-Lerma JA, Burgos-Martínez G, Alvarez-Etchegaray SE, Pelaez-Ballestas I, Vázquez-Mellado J: [Measurement of health-related quality of life and functional capacity in patients with chronic tophaceous gout]. Reumatol Clin; 2009 May-Jun;5(3):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of health-related quality of life and functional capacity in patients with chronic tophaceous gout].
  • [Transliterated title] Medición de la calidad de vida asociada a la salud y a la capacidad funcional en pacientes con gota crónica tofácea.
  • It is not known if generic instruments such as the MOS-20, or specific for other illnesses, such as the AIMS, can be applied to patients with Gout.
  • OBJECTIVE: To evaluate the clinimetric characteristic of the MOS-20 and AIMS questionnaires, and their correlation with HAQ-DI, as well as with clinical variables in patient with tophaceous gout (TG).
  • The MOS-20 had an αC of 0.68 to 1.0 and a ICC of 0.27 to 0.61 between the several components.
  • The AIMS had an αC of 0.66 to 0.96, and a ICC of 0.11 to 0.79 between the several components.
  • Reliability was better between the physical components in MOS-20 and AIMS.
  • The MOS-20, AIMS and the HAQ-DI correlated with the presence of joints with functional limitation.
  • The HAQ-DI was best correlated with the physical component than with the mental component of the AIMS and the MOS-20.
  • CONCLUSION: The AIMS, the MOS-20 and the HAQ-DI are useful in measuring the functional capacity and the quality of life in patient with TG.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier España, S.L. All rights reserved.
  • (PMID = 21794590.001).
  • [ISSN] 1699-258X
  • [Journal-full-title] Reumatología clinica
  • [ISO-abbreviation] Reumatol Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Buffart TE, Coffa J, Hermsen MA, Carvalho B, van der Sijp JR, Ylstra B, Pals G, Schouten JP, Meijer GA: DNA copy number changes at 8q11-24 in metastasized colorectal cancer. Cell Oncol; 2005;27(1):57-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: C-Myc, a well-known oncogene located on 8q24.12-q24.23, is often amplified and over-expressed in both primary and metastasizing colorectal cancer.
  • Therefore, the present study aims to correlate DNA copy number status of a series of genes at 8q23-24 in colorectal cancer at high resolution in correlation to metastatic disease.
  • Astler-Coller B1 and B2 colorectal cancers differed significantly in DNA copy number of the genes, MOS (p=0.04), MYC (p=0.007), DDEF1 (p=0.004), PTK2 (p=0.02) and PTP4A3 (p=0.04).
  • When comparing these with Astler-Coller D primary tumors, significant differences were seen for several genes as well (MYC (p<0.000), DDEF1 (p<0.000), SLA (p<0.000), PTK2 (p<0.000), PTP4A3 (p=0.002), and RECQL4 (p=0.01)).
  • When comparing primary Astler-Coller D tumors and their corresponding liver metastases, a similar pattern of gains and losses was observed.
  • Most of the liver metastases showed higher DNA copy number ratios than the corresponding primary tumors, but this difference was only significant for TPD52 (p=0.02) and EIF3S6 (p=0.007).
  • CONCLUSION: In addition to c-myc, multiple genes on chromosome 8 differed significantly between primary colorectal cancers with and without liver metastases.
  • This observation is consistent with the concept that clinical behaviour, like risk of liver metastasis, is determined by the genomic profile that is already present in the primary tumor.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750208.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Immediate-Early Proteins; 0 / Neoplasm Proteins; 0 / Oligonucleotides; 9007-49-2 / DNA; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC4611113
  •  go-up   go-down


79. Hogan WJ, Litzow MR, Tefferi A: Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep; 2007 Feb;2(1):34-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
  • Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors.
  • It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera.
  • The only curative option is allogeneic hematopoietic cell trans-plantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients.
  • Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short.
  • Complications such as graft-versus-host disease remain the major barrier to greater success.
  • At present this modality is generally restricted to younger patients with intermediate-to high-risk disease.
  • We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis.
  • We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Primary Myelofibrosis / surgery

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2005 Aug;32(4):414-21 [16202687.001]
  • [Cites] Am J Hematol. 1998 Jan;57(1):24-8 [9423812.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):1010-6 [9326205.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):1004-9 [9326204.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1013-8 [8704209.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):769-72 [12437657.001]
  • [Cites] Blood. 1999 May 1;93(9):2831-8 [10216077.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7 [16365288.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1656-60 [16104040.001]
  • [Cites] Blood. 2001 Aug 1;98(3):586-93 [11468154.001]
  • [Cites] Cancer. 2006 May 1;106(9):1985-9 [16568439.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):953-4 [15244400.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):245-6 [11918562.001]
  • [Cites] Blood. 1986 Jun;67(6):1693-7 [3518834.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2534-41 [12517815.001]
  • [Cites] Blood. 2005 May 15;105(10):4115-9 [15671439.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4274-81 [16478879.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):883-9 [15244384.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2180-1 [11286221.001]
  • [Cites] Br J Haematol. 1990 May;75(1):4-9 [2375922.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):690-7 [15725091.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2255-8 [11877308.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2226-33 [10733489.001]
  • [Cites] Cancer. 1991 May 15;67(10):2658-63 [2015567.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):430-3 [10691877.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1255-65 [10781623.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1158-64 [16609064.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):635-40 [9207412.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4667-73 [8541560.001]
  • [Cites] N Engl J Med. 2000 Aug 31;343(9):659; author reply 659-60 [10979803.001]
  • [Cites] Am J Hematol. 1999 May;61(1):10-5 [10331505.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(6):697-9 [11035377.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Cell. 1998 May 1;93(3):385-95 [9590173.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):807-13 [15354205.001]
  • [Cites] Blood Rev. 1997 Dec;11(4):233-42 [9481452.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):775-6 [11236794.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):166-71 [16197445.001]
  • [Cites] Cell. 1998 May 1;93(3):397-409 [9590174.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3912-8 [12920019.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):35-40 [12815476.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):623-30 [16369987.001]
  • (PMID = 20425386.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Myeloablative Agonists; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 48
  •  go-up   go-down


80. Zdunczyk Z, Juskiewicz J, Jankowski J, Biedrzycka E, Koncicki A: Metabolic response of the gastrointestinal tract of turkeys to diets with different levels of mannan-oligosaccharide. Poult Sci; 2005 Jun;84(6):903-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different levels of dietary mannan-oligosaccharide (MOS) administered for 16 wk to commercial male turkeys were evaluated for their efficacy on performance and on microbial activity in the digestive tract.
  • The following levels of MOS were used in a diet: low (0.1% during the entire study), medium (0.4 and 0.2% in the first and second 8-wk periods, respectively), and high (1.0 and 0.4% in the first and second 8-wk periods, respectively).
  • After 16 wk of experimental feeding, the diet intake was similar in all groups examined, whereas the live BW was significantly higher in groups with medium and high levels of MOS compared with the control group and birds fed a diet containing a low level of mannan.
  • The highest ammonia concentration in the cecal digesta was associated with a low dose of mannan in a diet, and the concentration was reduced to the control level when both higher doses of MOS were used.
  • The concentration of short-chain fatty acids in the ceca decreased with increasing amounts of MOS in a diet, especially in the case of acetate.
  • Dietary MOS did not significantly affect the cecal populations of Bifidobacterium and Lactobacillus.

  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971528.001).
  • [ISSN] 0032-5791
  • [Journal-full-title] Poultry science
  • [ISO-abbreviation] Poult. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Mannans; 0 / Oligosaccharides; 7664-41-7 / Ammonia
  •  go-up   go-down


81. Kvasnicka HM, Thiele J: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol; 2010 Jan;85(1):62-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prodromal myeloproliferative neoplasms: the 2008 WHO classification.
  • The concept of prodromal chronic myeloproliferative neoplasms has been endorsed by the WHO classification implicating a stepwise evolution of disease.
  • Histology of the bone marrow (BM) and borderline to mildly expressed clinical features play a pivotal role for diagnosing prefibrotic-early primary myelofibrosis.
  • Pre-polycythemic stages of polycythemia vera with a low hemoglobin level at onset are diagnosed by positive JAK2V617F mutation status, a low erythropoietin value, and characteristic BM features.
  • The revised WHO classification incorporates hematological, morphological, and molecular-genetic parameters to generate a consensus-based working diagnosis.
  • [MeSH-major] Polycythemia Vera / pathology. Primary Myelofibrosis / pathology. Thrombocythemia, Essential / pathology
  • [MeSH-minor] Bone Marrow Examination. Disease Progression. Erythrocyte Volume. Erythropoietin / blood. Female. Humans. Janus Kinase 2 / genetics. Male. Mutation. Platelet Count. Risk. World Health Organization

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19844986.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 141
  •  go-up   go-down


82. Janardhana V, Broadway MM, Bruce MP, Lowenthal JW, Geier MS, Hughes RJ, Bean AG: Prebiotics modulate immune responses in the gut-associated lymphoid tissue of chickens. J Nutr; 2009 Jul;139(7):1404-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we studied the effect of the prebiotics mannan-oligosaccharide (MOS) and fructo-oligosaccharide (FOS) on the phenotypic and functional competence of immune cells in cecal tonsil (CT), which is a major GALT.
  • Chickens in experimental groups received 0.05 g/kg zinc bacitracin or 5 g/kg of either FOS or MOS in addition to basal diet.

  • Hazardous Substances Data Bank. BACITRACIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474157.001).
  • [ISSN] 1541-6100
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 1405-87-4 / Bacitracin
  •  go-up   go-down


83. Weiss DJ: Bone marrow pathology in dogs and cats with non-regenerative immune-mediated haemolytic anaemia and pure red cell aplasia. J Comp Pathol; 2008 Jan;138(1):46-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow pathology in dogs and cats with non-regenerative immune-mediated haemolytic anaemia and pure red cell aplasia.
  • Many dogs and cats with immune-mediated haemolytic anaemia (IMHA) lack a bone marrow erythroid regenerative response.
  • To better understand the failure of the bone marrow to respond to the anaemia, bone marrow pathology associated with non-regenerative IMHA and pure red cell aplasia (PRCA) was reviewed.
  • Fifty-five dogs had non-regenerative IMHA (38 had bone marrow erythroid hyperplasia and 17 had erythroid maturation arrest) and 27 had pure red cell aplasia (PRCA).
  • Twenty-eight cats had non-regenerative IMHA (24 had erythroid hyperplasia and 4 had erythroid maturation arrest) and 29 had PRCA.
  • A variety of pathological changes were observed in bone marrow aspirates and core biopsy specimens taken from these animals.
  • These changes included dysmyelopoiesis, myelonecrosis, myelofibrosis, interstitial oedema, haemorrhage, acute inflammation, haemophagocytic syndrome, lymphocyte aggregation, and lymphocyte or plasma cell hyperplasia.
  • In both dogs and cats, dysmyelopoiesis, myelonecrosis, myelofibrosis, interstitial oedema, haemorrhage, acute inflammation and haemophagocytic syndrome were primarily noted in bone marrow specimens where there was evidence of erythroid hyperplasia.
  • These animals were also more often neutropenic and thrombocytopenic, and had decreased 60 day survival when compared with dogs or cats with non-regenerative anaemia associated with erythroid maturation arrest or PRCA.
  • Therefore, the pathogenesis of the non-regenerative anaemia in non-regenerative IMHA may involve both antibody-mediated destruction of bone marrow precursor cells and pathological events within the bone marrow that result in ineffective erythropoiesis.
  • [MeSH-major] Anemia, Hemolytic / veterinary. Bone Marrow / pathology. Bone Marrow Cells / pathology. Cat Diseases / pathology. Dog Diseases / pathology. Red-Cell Aplasia, Pure / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083185.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Torrecillas S, Makol A, Caballero MJ, Montero D, Robaina L, Real F, Sweetman J, Tort L, Izquierdo MS: Immune stimulation and improved infection resistance in European sea bass (Dicentrarchus labrax) fed mannan oligosaccharides. Fish Shellfish Immunol; 2007 Nov;23(5):969-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to determine the effect of two levels of inclusion of mannan oligosaccharides derived from the outer cell wall of a select strain of Saccharomyces cerevisiae (Bio-Mos, Alltech Inc, USA) on growth, feed utilization, immune status and disease resistance of European sea bass (Dicentrarchus labrax).
  • Specimens of 35 g at initial density of 3 kg/m3 were fed during 67 days at 0 per thousand, 2 per thousand and 4 per thousand dietary MOS level of inclusion in a commercial sea bass diet.
  • Growth significantly increased at both MOS dietary inclusion levels.
  • Statistical differences (P<0.05) on the phagocytic index were denoted with the inclusion of 4 per thousand Bio-Mos group.
  • A positive correlation was found between the levels of lysozyme and alternative complement pathway activities in blood and the level of inclusion of MOS in diets.
  • Twenty-one days post-challenge the number of cohabitant fish infected in the control group reached 33% comparing with none on the 0.4 per thousand MOS group.
  • After 24h post-infection no significant difference was denoted between groups and 48 h post-infection total infected fish in the control group was twice that of the 2 per thousand and 4 per thousand MOS groups.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766145.001).
  • [ISSN] 1050-4648
  • [Journal-full-title] Fish & shellfish immunology
  • [ISO-abbreviation] Fish Shellfish Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Mannans; 0 / Oligosaccharides
  •  go-up   go-down


85. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, Geiger D, Cetin M, Khayat M, Kleta R, Kfir N, Anikster Y, Chezar J, Arcos-Burgos M, Shalata A, Stanescu H, Manaster J, Arat M, Edwards H, Freiberg AS, Hart PS, Riney LC, Patzel K, Tanpaiboon P, Markello T, Huizing M, Maric I, Horne M, Kehrel BE, Jurk K, Hansen NF, Cherukuri PF, Jones M, Cruz P, Mullikin JC, Nurden A, White JG, Gahl WA, Falik-Zaccai T: Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood; 2010 Dec 02;116(23):4990-5001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.
  • Gray platelet syndrome (GPS) is an inherited bleeding disorder characterized by macrothrombocytopenia and absence of platelet α-granules resulting in typical gray platelets on peripheral smears.
  • GPS is associated with a bleeding tendency, myelofibrosis, and splenomegaly.
  • We present the results of molecular genetic analysis of 116 individuals including 25 GPS patients from 14 independent families as well as novel clinical data on the natural history of the disease.
  • Long-term follow-up data demonstrated the progressive nature of the thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in some patients.
  • We identified high serum vitamin B(12) as a consistent, novel finding in GPS.
  • Chromosome 3p21.1-3p22.1 has not been previously linked to a platelet disorder; identification of the GPS gene will likely lead to the discovery of novel components of platelet organelle biogenesis.


86. Rachmuth G, Poon CS: Transistor analogs of emergent iono-neuronal dynamics. HFSP J; 2008 Jun;2(3):156-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuromorphic analog metal-oxide-silicon (MOS) transistor circuits promise compact, low-power, and high-speed emulations of iono-neuronal dynamics orders-of-magnitude faster than digital simulation.
  • Here we present versatile neuromorphic analog building-block circuits that afford near-maximum voltage dynamic range operating within the low-power MOS transistor weak-inversion regime which is ideal for aVLSI implementation or implantable biomimetic device applications.
  • As a critical performance benchmark, the high-speed and highly interactive iono-neuronal simulation capability on-chip enabled our prompt discovery of a minimal model of chaotic pacemaker bursting, an emergent iono-neuronal behavior of fundamental biological significance which has hitherto defied experimental testing or computational exploration via conventional digital or analog simulations.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neural Comput. 2007 Feb;19(2):327-50 [17206867.001]
  • [Cites] Neural Comput. 2007 Oct;19(10):2581-603 [17716003.001]
  • [Cites] Science. 2006 Oct 6;314(5796):80-5 [17023649.001]
  • [Cites] IEEE Trans Neural Netw. 2006 Mar;17(2):496-508 [16566475.001]
  • [Cites] IEEE Trans Neural Netw. 2006 Jan;17(1):211-21 [16526488.001]
  • [Cites] J Neural Eng. 2006 Mar;3(1):21-34 [16510939.001]
  • [Cites] Nat Rev Neurosci. 2006 Feb;7(2):153-60 [16429124.001]
  • [Cites] IEEE Eng Med Biol Mag. 2005 Sep-Oct;24(5):22-9 [16248114.001]
  • [Cites] Neuron. 2005 Mar 24;45(6):917-28 [15797552.001]
  • [Cites] J Comput Neurosci. 1999 Jul-Aug;7(1):33-9 [10482000.001]
  • [Cites] J Neurophysiol. 1999 Jul;82(1):115-22 [10400940.001]
  • [Cites] Nature. 1999 May 13;399(6732):151-5 [10335844.001]
  • [Cites] Nat Med. 1998 Oct;4(10):1173-6 [9771751.001]
  • [Cites] Neural Comput. 1998 Oct 1;10(7):1601-38 [9744889.001]
  • [Cites] Nature. 1997 Oct 2;389(6650):492-5 [9333237.001]
  • [Cites] Trends Neurosci. 1996 Apr;19(4):130-7 [8658595.001]
  • [Cites] Nature. 1991 Dec 19-26;354(6354):515-8 [1661852.001]
  • [Cites] J Neurosci. 2004 Jun 9;24(23):5427-38 [15190116.001]
  • [Cites] Trends Neurosci. 2004 Apr;27(4):218-24 [15046881.001]
  • [Cites] IEEE Trans Biomed Eng. 2004 Feb;51(2):342-54 [14765707.001]
  • [Cites] Nat Rev Neurosci. 2004 Jan;5(1):13-23 [14661065.001]
  • [Cites] Physiol Rev. 2003 Oct;83(4):1401-53 [14506309.001]
  • [Cites] Curr Opin Neurobiol. 2002 Dec;12(6):646-51 [12490254.001]
  • [Cites] Trends Neurosci. 2002 Nov;25(11):558-63 [12392930.001]
  • [Cites] J Neurophysiol. 2001 Jul;86(1):59-74 [11431488.001]
  • [Cites] Ann Biomed Eng. 2001 Oct;29(10):897-907 [11764320.001]
  • [Cites] Neural Netw. 2001 Jul-Sep;14(6-7):617-28 [11665758.001]
  • [Cites] IEEE Trans Neural Syst Rehabil Eng. 2001 Sep;9(3):319-26 [11561669.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10457-62 [11526244.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1159-63 [11498596.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7107-12 [11416195.001]
  • [Cites] Biol Cybern. 2000 Jun;82(6):517-27 [10879435.001]
  • [Cites] IEEE Trans Neural Netw. 2003;14(5):1297-307 [18244578.001]
  • [Cites] IEEE Trans Neural Syst Rehabil Eng. 2006 Dec;14(4):410-8 [17190033.001]
  • (PMID = 19404469.001).
  • [ISSN] 1955-2068
  • [Journal-full-title] HFSP journal
  • [ISO-abbreviation] HFSP J
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL072849; United States / NHLBI NIH HHS / HL / R01 HL079503; United States / NIBIB NIH HHS / EB / R21 EB005460
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Other-IDs] NLM/ PMC2645565
  •  go-up   go-down


87. Cao SF, Li D, Yuan Q, Guan X, Xu C: Spatial and temporal expression of c-mos in mouse testis during postnatal development. Asian J Androl; 2008 Mar;10(2):277-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial and temporal expression of c-mos in mouse testis during postnatal development.
  • AIM: To immunolocalize the c-mos gene product and to investigate its spatial and temporal expression in mouse testis during postnatal development.
  • METHODS: Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization techniques were used to examine c-mos mRNA and indirect immunofluorescence was used to localize c-Mos protein in mouse testis on postnatal days 14, 21, 25, 28, 30, 35, 49 and 70.
  • RESULTS: c-mos mRNA remained low on postnatal days 14-21, increased abruptly from day 25 and peaked on day 30.
  • Its levels decreased a little on day 35 and became almost stable thereafter until day 70. c-mos mRNA was localized in the nucleus and cytoplasm of the spermatocytes and round spermatids.
  • Using a polyclonal anti-c-Mos antibody, Western blotting detected a single band at 43 kDa in testis lysate. c-Mos protein was exclusively localized to the elongating spermatids and was first detected on postnatal day 30.
  • The number of c-Mos-positive spermatids increased progressively till day 49 and stabilized thereafter.
  • CONCLUSION: The c-mos gene displays a spatial and temporal expression pattern in the mouse testis during postnatal development at both the mRNA and protein level.
  • This suggests that c-mos might play important roles in spermatogenesis.
  • [MeSH-major] Genes, mos / genetics. Spermatocytes / metabolism. Spermatogenesis / genetics. Testis / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097537.001).
  • [ISSN] 1008-682X
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Smith SJ, Whaley CM, Rauchfuss TB, Wilson SR: MS2(Me2PC2H4PMe2)2 (M = Mo, W): acid-base properties, proton transfer, and reversible protonolysis of sulfido ligands. Inorg Chem; 2006 Jan 23;45(2):679-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The acid-base reactivity of MS(2)(dmpe)(2), where M = Mo (1) and W (2) and dmpe = Me(2)PCH(2)CH(2)PMe(2), was examined.
  • The pK(a)'s of the Mo and W compounds are estimated to be 16.5 and 15.5, respectively.
  • Treatment of 1 with excess HOTf liberates H(2)S to afford [MoS(OTf)(dmpe)(2)]OTf, which forms an adduct with CD(3)CN and regenerates 1 upon treatment with SH(-)/Et(3)N solutions.
  • Consistent with its ready protonation, complex 1 is methylated, and the use of excess MeOTf gives [MoS(OTf)(dmpe)(2)](+) and Me(2)S in a rare example of double alkylation at a sulfido ligand.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411703.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Holt RF, Svirsky MA: An exploratory look at pediatric cochlear implantation: is earliest always best? Ear Hear; 2008 Aug;29(4):492-511
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infants younger than 12 mos currently are excluded from Food and Drug Administration clinical trials, but have been implanted with Food and Drug Administration-approved devices.
  • With a chance that an infant without profound hearing loss could be implanted because of the limitations of the diagnostic measures used with this population and the potential for additional anesthetic risks to infants younger than 1-yr-old, it is prudent to evaluate benefit in the youngest cochlear implant recipients.
  • Spoken language scores and rate of development were evaluated along with four covariates (unaided pure-tone average, communication mode, gender, and estimated family income) as a function of age at implantation.
  • CONCLUSIONS: Although in general earlier cochlear implantation led to better outcomes, there were few differences in outcome between the small sample of six children implanted before 12 mos of age and those implanted at 13 to 24 mos.
  • [MeSH-minor] Age Factors. Audiometry, Evoked Response. Audiometry, Pure-Tone. Auditory Threshold. Child. Child, Preschool. Critical Period (Psychology). Diagnosis, Computer-Assisted. Humans. Infant. Language Development Disorders / diagnosis. Language Development Disorders / rehabilitation. Otoacoustic Emissions, Spontaneous. Prognosis. Sensitivity and Specificity. Software. Speech Reception Threshold Test

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ear Hear. 2004 Jun;25(3):302-7 [15179120.001]
  • [Cites] Audiol Neurootol. 2001 Nov-Dec;6(6):363-80 [11847464.001]
  • [Cites] Ear Hear. 2000 Oct;21(5):471-87 [11059705.001]
  • [Cites] Anesth Analg. 1990 Feb;70(2):160-7 [2301747.001]
  • [Cites] Pediatrics. 2005 Oct;116(4):e487-93 [16199675.001]
  • [Cites] Ear Hear. 1999 Jun;20(3):238-52 [10386850.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 1982 Mar-Apr;91(2 Pt 3):67-73 [6805401.001]
  • [Cites] J Speech Hear Disord. 1977 Aug;42(3):328-34 [881813.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 1999 Apr;177:119-23 [10214815.001]
  • [Cites] Pediatrics. 1961 Nov;28:697-704 [14489693.001]
  • [Cites] Anesthesiology. 1996 Nov;85(5):977-87 [8916813.001]
  • [Cites] Ear Hear. 1992 Jun;13(3):187-94 [1397759.001]
  • [Cites] Laryngoscope. 1999 Apr;109(4):595-9 [10201747.001]
  • [Cites] Audiol Neurootol. 2004 Jul-Aug;9(4):224-33 [15205550.001]
  • [Cites] Neuroreport. 2002 Jul 19;13(10):1365-8 [12151804.001]
  • [Cites] Ear Hear. 2003 Feb;24(1 Suppl):24S-35S [12612478.001]
  • [Cites] Ear Hear. 1999 Aug;20(4):345-62 [10466570.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 2002 May;189:22-8 [12018343.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Sep;117(3 Pt 1):180-7 [9334763.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 2000 Dec;185:99-100 [11141026.001]
  • [Cites] Annu Rev Psychol. 2002;53:371-99 [11752490.001]
  • [Cites] Acta Otolaryngol. 2003 Jan;123(2):249-52 [12701751.001]
  • [Cites] Ear Hear. 2003 Feb;24(1 Suppl):106S-20S [12612485.001]
  • [Cites] Child Dev. 2003 Sep-Oct;74(5):1368-78 [14552403.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 2000 Dec;185:92-3 [11141023.001]
  • [Cites] J Speech Lang Hear Res. 1997 Feb;40(1):183-99 [9113869.001]
  • [Cites] Ear Hear. 1998 Feb;19(1):48-61 [9504272.001]
  • [Cites] Ear Hear. 2000 Oct;21(5):508-28 [11059707.001]
  • [Cites] Psychol Sci. 2000 Mar;11(2):153-8 [11273423.001]
  • [Cites] JAMA. 1985 Apr 26;253(16):2373-7 [3981764.001]
  • [Cites] Scand Audiol Suppl. 1999;51:13-22 [10803910.001]
  • [Cites] Ear Hear. 2004 Dec;25(6):539-53 [15604915.001]
  • [Cites] Br J Anaesth. 1988 Sep;61(3):263-9 [3179147.001]
  • [Cites] Anesthesiology. 2000 Jul;93(1):6-14 [10861140.001]
  • [Cites] J Assoc Res Otolaryngol. 2001 Dec;2(4):297-311 [11833605.001]
  • [Cites] Anesthesiol Clin North America. 2002 Mar;20(1):1-28, v [11892500.001]
  • [Cites] J Clin Anesth. 1991 Nov-Dec;3(6):433-7 [1760163.001]
  • [Cites] Paediatr Anaesth. 2001 Nov;11(6):711-8 [11696149.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Jul;68(7):915-26 [15183583.001]
  • [Cites] Ear Hear. 2007 Apr;28(2 Suppl):11S-18S [17496638.001]
  • [Cites] Anesthesiology. 1994 May;80(5):976-82 [8017662.001]
  • [Cites] Acta Anaesthesiol Scand. 1988 Nov;32(8):653-64 [3213390.001]
  • [Cites] Ear Hear. 1997 Dec;18(6):440-55 [9416447.001]
  • (PMID = 18382374.001).
  • [ISSN] 1538-4667
  • [Journal-full-title] Ear and hearing
  • [ISO-abbreviation] Ear Hear
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC003937-11; United States / NIDCD NIH HHS / DC / T32 DC00012; United States / NIDCD NIH HHS / DC / R01 DC00423; United States / NIDCD NIH HHS / DC / R01 DC000423; United States / NIDCD NIH HHS / DC / T32 DC000012; United States / NIDCD NIH HHS / DC / R01 DC003937; United States / NIDCD NIH HHS / DC / R01 DC03937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


90. Takeuchi T, Tanigawa Y, Minamide R, Ikenishi K, Komiya T: Analysis of SDF-1/CXCR4 signaling in primordial germ cell migration and survival or differentiation in Xenopus laevis. Mech Dev; 2010 Jan-Feb;127(1-2):146-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) Whether injection of antisense morpholino oligos (MOs) for CXCR4 mRNA into vegetal blastomere containing the germ plasm or the precursor of PGCs disturbs the migration of PGCs?
  • (2) Whether injection of exogenous CXCR4 mRNA together with MOs can restore the knockdown phenotype?

  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19770040.001).
  • [ISSN] 1872-6356
  • [Journal-full-title] Mechanisms of development
  • [ISO-abbreviation] Mech. Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / RNA, Messenger; 0 / Receptors, CXCR4; 0 / SDF-1 protein, Xenopus; 0 / Xenopus Proteins
  •  go-up   go-down


91. Wu HC, Chou P, Chou FH, Su CY, Tsai KY, Ou-Yang WC, Su TT, Chao SS, Sun WJ, Chen MC: Survey of quality of life and related risk factors for a Taiwanese village population 3 years post-earthquake. Aust N Z J Psychiatry; 2006 Apr;40(4):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trained assistants used the Medical Outcomes Study Short Form-36 (MOS SF-36) and questionnaires to interview 405 respondents (189 men and 216 women) aged 16 years or older, who had been exposed to the earthquake.
  • RESULTS: The prevalence range for psychiatric disorders in the earthquake survivors was 0.2-7.2% 3 years after the Chi-Chi earthquake, with rates for major depression (MD) and posttraumatic stress disorder (PTSD) of 6.4% and 4.4%, respectively.
  • The QOL scores for the PTSD/MD group were lower than for the other two diagnostic groups, as determined by assessment of physical and mental aspects of functional integrity from MOS SF-36 scores.
  • The predictors for poor QOL were age, female gender, economic problems, physical illness, subjective assessment of memory and social-activity decline and diagnosis of PTSD or MD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Mental Disorders / diagnosis. Mental Disorders / epidemiology. Mental Disorders / etiology. Middle Aged. Risk Factors. Severity of Illness Index. Taiwan / epidemiology. Time Factors


92. Oshiro M, Nonoyama K, Oliveira RA, Barretto OC: Red cell aspartate aminotransferase saturation with oral pyridoxine intake. Sao Paulo Med J; 2005 Mar 2;123(2):54-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vitamin B6-responsive sideroblastic anemia, myelofibrosis and Peyronies syndrome respond to high pyridoxine doses.
  • However, the 200-mg dose could be employed safely in vitamin B6-responsive sideroblastic anemia, myelofibrosis and Peyronies syndrome treatment.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • Hazardous Substances Data Bank. PYRIDOXINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947830.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 5V5IOJ8338 / Pyridoxal Phosphate; EC 2.6.1.1 / Aspartate Aminotransferases; KV2JZ1BI6Z / Pyridoxine
  •  go-up   go-down


93. Helmke BM, Renner M, Poustka A, Schirmacher P, Mollenhauer J, Kern MA: DMBT1 expression distinguishes anorectal from cutaneous melanoma. Histopathology; 2009 Jan;54(2):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DMBT1 expression distinguishes anorectal from cutaneous melanoma.
  • AIMS: Anorectal melanoma (AM) forms a rare but highly malignant subset of mucosal melanoma with an extremely poor prognosis.
  • Although AMs display histological and immunohistochemical features very similar to cutaneous melanoma (CM), no association exists either with exposure to ultraviolet light or with melanocytic naevi.
  • The aim was to carry out expression analyses of classical immunohistochemical markers and of the protein deleted in malignant brain tumours 1 (DMBT1) in cases of primary anorectal malignant melanoma and CM.
  • METHODS AND RESULTS: Expression analyses of classical immunohistochemical markers (S100, HMB45, Melan A and MiTF) and of the protein DMBT1 were carried out in 27 cases of primary anorectal malignant melanoma and 26 cases of CM.
  • All AM cases analysed showed expression of at least three of the classical markers for melanoma.
  • CONCLUSION: These results identify DMBT1 as a molecular feature that may allow distinction between AM and CM and support the notion that AM represents an entity molecularly distinct from CM.
  • [MeSH-major] Anus Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Melanoma / diagnosis. Receptors, Cell Surface / biosynthesis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207948.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DMBT1 protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


94. Nunoda K, Sashida G, Ohyashiki K, Kodama A, Fukutake K: The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint. Cancer Genet Cytogenet; 2006 Jan 1;164(1):90-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint.
  • [MeSH-major] Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 4. Myelodysplastic Syndromes / genetics. Primary Myelofibrosis / genetics. Translocation, Genetic


95. Iezzoni LI, Rao SR, Kinkel RP: Experiences acquiring and using mobility aids among working-age persons with multiple sclerosis living in communities in the United States. Am J Phys Med Rehabil; 2010 Dec;89(12):1010-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite owning mobility aids, many had not used this equipment in the previous 12 mos, including 4.5% of power wheelchair owners, 13.8% of those with manual wheelchairs, and 9.3% of scooter owners.


96. Rai P, Lee BM, Liu TY, Yuhui Q, Krause E, Marsman DS, Felter S: Safety evaluation of disposable baby diapers using principles of quantitative risk assessment. J Toxicol Environ Health A; 2009;72(21-22):1262-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The safety profile of a diaper is determined by the biological properties of individual components and the extent to which the baby is exposed to each component during use.
  • This assessment of potential exposure is then combined with data from standard safety assessments of components to determine the margin of safety (MOS).

  • Hazardous Substances Data Bank. CITRAL .
  • Hazardous Substances Data Bank. SODIUM ACRYLATE .
  • Hazardous Substances Data Bank. Acrylic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077195.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acrylates; 0 / Monoterpenes; 0 / Perfume; J94PBK7X8S / acrylic acid; T7EU0O9VPP / citral
  •  go-up   go-down


97. Johnson ES, Zhou Y, Lillian Yau C, Prabhakar D, Ndetan H, Singh K, Preacely N: Mortality from malignant diseases-update of the Baltimore union poultry cohort. Cancer Causes Control; 2010 Feb;21(2):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality from malignant diseases-update of the Baltimore union poultry cohort.
  • We previously studied mortality up to 1989 in 2,639 members of a local union who had ever worked in poultry slaughtering and processing plants, because they were exposed to oncogenic viruses present in poultry.
  • Compared to the US general population, an excess of cancers of the buccal and nasal cavities and pharynx (base of the tongue, palate and other unspecified mouth, tonsil and oropharynx, nasal cavity/middle ear/accessory sinus), esophagus, recto-sigmoid/rectum/anus, liver and intrabiliary system, myelofibrosis, lymphoid leukemia and multiple myeloma was observed in particular subgroups or in the entire poultry cohort.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847658.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA 30410-3; United States / NIOSH CDC HHS / OH / 1 R01 OH008071
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Ruiz-Pérez I, Olry de Labry-Lima A, López-Ruz MA, del Arco-Jiménez A, Rodríguez-Baño J, Causse-Prados M, Pasquau-Liaño J, Martín-Rico P, Prada-Pardal JL, de la Torre-Lima J, López-Gómez M, Marcos M, Muñoz N, Morales D, Muñoz I: [Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment]. Enferm Infecc Microbiol Clin; 2005 Dec;23(10):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Estado clínico, adherencia al TARGA y calidad de vida en pacientes con infección por el VIH tratados con antirretrovirales.
  • INTRODUCTION: Quality of life is one of the most frequently used subjective measures in chronic health problems.
  • Health-related quality of life was assessed with the MOS-HIV questionnaire, an instrument designed specifically for HIV-infected patients.
  • No statistically significant differences in the domain scores except for quality of life were found between patients with a treatment regimen including protease inhibitors and those without.


99. Lee KK, Cho HI, Chi HS, Kim DY, Chae SL, Huh HJ: [A case of post-essential thrombocythemia myelofibrosis with severe osteosclerosis]. Korean J Lab Med; 2010 Apr;30(2):122-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of post-essential thrombocythemia myelofibrosis with severe osteosclerosis].
  • Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage.
  • After many years, a few patients with ET may develop bone marrow (BM) fibrosis and rarely develop osteosclerosis.
  • BM biopsy showed clusters of dysplastic megakaryocytes, grade 3 fibrosis, and severe osteosclerosis.
  • According to the 2008 WHO diagnostic criteria, the patient was diagnosed as having post-essential thrombocythemia myelofibrosis with severe osteosclerosis.
  • [MeSH-major] Osteosclerosis / diagnosis. Primary Myelofibrosis / diagnosis. Thrombocythemia, Essential / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Female. Humans. Megakaryocytes / pathology. Middle Aged. Splenomegaly / etiology. Tomography, X-Ray Computed


100. Frederix PL, Bosshart PD, Akiyama T, Chami M, Gullo MR, Blackstock JJ, Dooleweerdt K, de Rooij NF, Staufer U, Engel A: Conductive supports for combined AFM-SECM on biological membranes. Nanotechnology; 2008 Sep 24;19(38):384004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Highly oriented pyrolytic graphite (HOPG), MoS(2), template stripped gold, and template stripped platinum are compared as supports for high resolution imaging of reconstituted membrane proteins or native membranes, and as electrodes for transferring electrons from or to a redox molecule.
  • Electrochemical feedback experiments with conductive cantilevers that feature nanometre-scale electrodes showed fast re-oxidation of the redox couple Ru(NH(3))(6)(3+/2+) with the two metal supports after prolonged immersion in electrolyte.
  • In contrast, the re-oxidation rates decayed quickly to unpractical levels with HOPG or MoS(2) under physiological conditions.
  • On HOPG we observed heterogeneity in the re-oxidation rate of the redox molecules with higher feedback currents at step edges.
  • Rapid decay of re-oxidation rate and surface heterogeneity make HOPG or MoS(2) less attractive for combined AFM-SECM experiments on biological membranes than template stripped gold or platinum supports.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21832564.001).
  • [ISSN] 0957-4484
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement